25 Drugs The Default Library ======================================== The Real Harm Ladder -------------------- The most dangerous drug most people use is legal, sold at every gas station, and rarely thought of as a "drug" at all. Before the rest of this category goes substance by substance, here's what the actual published evidence says about which drugs cause the most harm — not which ones are illegal. "Don't do drugs" treats every substance as interchangeable — equally dangerous, equally worth an identical blanket warning. It isn't true, and it isn't even close. Some legal drugs cause more measurable harm than some illegal ones. Some drugs classified alongside heroin have never caused a documented overdose death. This piece exists to replace the flat warning with the actual picture, using the most rigorous published attempt to measure and compare drug harm directly. The most rigorous attempt to actually measure this In 2010, a panel of drug-policy and addiction experts led by British psychiatrist and neuropsychopharmacologist David Nutt published a landmark study in The Lancet, scoring 20 drugs across 16 separate criteria — nine measuring harm to the user themselves (addiction potential, mortality risk, damage to health) and seven measuring harm to others (crime, family and community damage, economic cost). Each drug received a combined score out of 100. It remains, over a decade later, the most methodologically serious public attempt to rank drug harm on evidence rather than legal status or public perception. What the study actually found Alcohol scored highest overall — more harmful, by this combined measure, than heroin or crack cocaine — driven mainly by its harm to others (drunk driving deaths, violence, family and economic damage): about 46 of its 72 points came from harm to others. Its harm to drinkers themselves (about 26 points) was also substantial, though below heroin, crack cocaine and methamphetamine on that measure alone. Tobacco outscored cannabis. Several drugs most people associate with maximum danger and severe legal punishment — LSD, psilocybin mushrooms, MDMA — landed near the very bottom of the entire list. Legal status and actual harm turned out to be only loosely related. That gap is the single most important thing to understand before reading anything else in this category. Test yourself before you see the real numbers The most convincing way to feel this gap is to notice your own assumptions first. Eight head-to-head match-ups, drawn directly from the study's published overall harm scores — pick the one you think scored higher, then see the real number. Match-up 1 of 8 · Score: 0 Next match-up → The full ladder, for the drugs covered in this category Not every substance in this category was part of the original 2010 study — DMT, 5-MeO-DMT, ayahuasca, raw opium, and fentanyl specifically weren't among the 20 drugs scored, mostly because population-level harm data for them is thinner or, for fentanyl, because its current overdose crisis mostly postdates the study. The bars below show the real published overall scores (out of 100) for the substances in this category that were included. Overall harm score (self + others combined), out of 100 Higher score = more total measured harm in this specific 2010 UK analysis. This is one rigorous study, not an eternal law of nature — dosage, frequency, method of use, drug purity, and individual health all change real-world risk enormously, and the drug supply itself has shifted since 2010 (fentanyl contamination, in particular, has made the opioid landscape considerably more dangerous than these numbers alone would suggest). What this ladder doesn't tell you A low score on this scale is not a safety certificate. It means "lower than the other 19 or so drugs studied here, on these particular criteria, in this particular country, at this particular time" — not "safe." Psilocybin scored low here partly because it has an extremely low overdose and addiction potential, which is genuinely true and worth knowing — but it can still trigger a severe psychological crisis in the wrong setting or the wrong person, covered honestly in this category's psilocybin piece. Context — dose, setting, individual health, drug interactions, and what's actually in the substance you're taking — changes real risk more than almost anything else, for every drug on this list. The takeaway The most rigorous published attempt to score drug harm found that legal status is a poor predictor of actual danger: alcohol topped the list, tobacco beat cannabis, and several severely punished drugs (LSD, psilocybin, MDMA) scored near the bottom. This doesn't mean any drug is "safe" — it means the categories most people use to think about drug risk (legal vs. illegal) don't track the actual evidence very well, and every piece in this category tries to replace that broad category with the real, specific picture for that one substance. Try this: before reading any individual piece in this category, notice which substances you already assumed were "worse" or "safer" than others — then check that assumption against what the piece actually says. If you or someone you know is struggling: in the US, SAMHSA's National Helpline is 1-800-662-4357, free and confidential, 24/7. This category is written for honest education and harm reduction, not as medical advice — if you have questions about your own or someone else's drug use, a doctor or addiction specialist can give guidance this library can't. Sources & Further Reading Sources. Harm scores and methodology reflect Nutt DJ, King LA, Phillips LD, "Drug harms in the UK: a multicriteria decision analysis," The Lancet, 2010 (376: 1558–1565), conducted by the Independent Scientific Committee on Drugs. 🌐 Search "Nutt 2010 Lancet drug harms multicriteria" for the full published study and complete 20-drug table 🌐 DrugScience.org.uk — the ongoing independent research organization founded by David Nutt 🌐 See each individual piece in this category for substance-specific history, dangers, and (where relevant) therapeutic research LSD: The Accident That Became a Movement, a Menace, and (Maybe) a Medicine -------------------------------------------------------------------------- A Swiss chemist synthesized it in 1938 while researching a completely different problem, set it aside as uninteresting, and only rediscovered its effects five years later by accident — absorbing a trace through his fingertips and experiencing what he described as a stream of fantastic, kaleidoscopic imagery. That accident produced one of the most powerful psychoactive substances ever discovered, active in doses measured in millionths of a gram, and one of the most legally punished. Here's the honest version: what LSD actually does, why it went from psychiatric tool to street drug to psychiatric tool again, and what current research does and doesn't support. From ergot fungus to Bicycle Day Albert Hofmann first synthesized LSD-25 (lysergic acid diethylamide) at Sandoz Laboratories while investigating compounds derived from ergot, a fungus that grows on rye. On April 16, 1943, he accidentally absorbed a small amount and experienced its effects for the first time; three days later, on April 19, he deliberately took what he assumed was a cautious dose — 250 micrograms, which turned out to be several times a typical active dose — and rode his bicycle home through what became a famously overwhelming experience. April 19 is still informally celebrated by psychedelic researchers and enthusiasts as "Bicycle Day." Psychiatric tool, then countercultural symbol, then Schedule I Through the 1950s and into the mid-1960s, LSD was legally available and used in serious psychiatric research — Canadian researchers pioneered "psychedelic therapy" for chronic alcoholism, giving patients a single large dose in a supported, prepared setting, and thousands of patients worldwide were treated across various trials during this period (methodologically weaker than what modern trials require, but a real and active field, not fringe). Popularity shifted sharply in the 1960s as LSD moved from clinics into the counterculture — Harvard psychologists Timothy Leary and Richard Alpert became its most visible public advocates, and it became entangled with the era's music, politics, and radical social questioning. That visibility provoked a backlash: the Controlled Substances Act of 1970 placed LSD in the most restrictive category, Schedule I, alongside heroin — legally asserting it has no accepted medical use and a high potential for abuse — which shut down virtually all legitimate research for roughly three decades. What it actually does, and the real dangers LSD is not physically addictive in the way opioids, alcohol, or nicotine are — there's no withdrawal syndrome, and tolerance builds so fast with repeated daily use that the drug becomes rapidly less effective, which naturally discourages compulsive use. It also has an extremely wide margin between an active dose and a physically lethal one; there is no well-documented case of a fatal LSD overdose from the drug's direct physiological toxicity alone. That doesn't make it safe. The real dangers are psychological and situational, not toxicological: Duration and unpredictability. A typical trip lasts 8–12 hours — far longer than most other psychedelics — during which judgment, risk perception, and reality-testing are all significantly altered. Most LSD-related injuries and deaths on record involve accidents (falls, traffic, drowning) during this extended window, not the drug itself. Psychological crisis. A "bad trip" can involve overwhelming fear, paranoia, or a terrifying loss of a stable sense of self, and can be genuinely traumatic without careful setting and support. In people with a personal or family history of psychosis or schizophrenia, LSD can trigger or unmask a serious psychotic episode — this is the single most important contraindication. HPPD. A small minority of users develop Hallucinogen Persisting Perception Disorder — recurring visual disturbances (trails, halos, static in vision) that can persist long after the drug has left the body. It's uncommon but real and not fully predictable in advance. Dose inconsistency. Because an active dose is so microscopically small, illicit blotter paper can vary significantly in strength between batches, making accidental overdose of the intended dose (not a toxic one, but a much more intense psychological experience than planned) a real practical risk. Dangerous interactions. Combining LSD with lithium (a common medication for bipolar disorder) has been linked to seizures and is specifically flagged as dangerous by harm-reduction organizations; MAOIs and other psychiatric medications can also interact unpredictably. LSD's physical safety profile is unusually good by drug standards. Its psychological safety profile depends almost entirely on who's taking it, in what state of mind, in what setting, and that's exactly the variable a legal ban can't control for. The therapeutic case, and where it stands now After decades of research shutdown, controlled clinical studies resumed in the 2000s. Current trials are investigating LSD for anxiety (particularly existential anxiety tied to serious illness), depression, and alcohol use disorder, generally using one or a few sessions combined with structured psychological support before and after — a fundamentally different model from daily medication. In 2026 an LSD-based drug (DT120, from Definium Therapeutics, formerly MindMed) reported three positive Phase 3 trials: one in major depression (June) and two in generalized anxiety disorder (August and September). In the Voyage anxiety trial, a single 100-microgram dose cut anxiety scores by 11.6 points at 12 weeks, against 6.2 on placebo. The company plans to apply for FDA approval in the first half of 2027, which puts it a step behind psilocybin, whose application is already under review (see the psilocybin piece). Microdosing (tiny, sub-perceptual doses) is a separate question: placebo-controlled studies so far, such as a 2021 self-blinding study in eLife, have mostly found effects no bigger than placebo. None of this is settled — regulatory review and real-world approval are still ahead — but the research base is now substantially more rigorous than anything available during the drug's first psychiatric era. Try this If you want to understand the actual scale of an LSD dose, look up a photo comparing a single grain of table salt to a typical 100-microgram dose of LSD — the visual is a fast, honest way to grasp both why so little produces such a large effect, and why dose consistency is such a real practical concern. The takeaway LSD was discovered by accident in 1943, used seriously in psychiatric research through the 1950s and '60s, then swept into Schedule I in 1970 largely for cultural and political reasons that shut down legitimate research for decades. It isn't physically addictive and has no documented direct-overdose deaths, but its real risks are psychological: a long, unpredictable trip, a genuine risk of triggering psychosis in vulnerable individuals, rare but real HPPD, and dangerous interactions with certain medications. Modern, more rigorous clinical trials are now investigating it for anxiety, depression, and alcohol use disorder, with positive Phase 3 results in 2026 and an FDA application planned for 2027. Try this: look up a real-scale comparison image of an active LSD dose against a grain of salt to grasp just how small an active dose actually is. Sources & Further Reading Sources - Hofmann's discovery and Bicycle Day reflect his own published account and standard chemical-history documentation. - The 1950s–60s Canadian psychedelic-therapy research for alcoholism and its later Schedule I classification under the 1970 Controlled Substances Act reflect documented drug-policy history. - HPPD, psychosis risk, lithium interaction warnings, and dose-consistency issues reflect published harm-reduction and clinical literature (e.g., from organizations including DanceSafe and the clinical psychiatric literature on hallucinogen persisting perception disorder). - Clinical trial status: Definium Therapeutics press releases on the Phase 3 Voyage (12 August 2026) and Panorama (14 September 2026) results in generalized anxiety disorder, and its plan to file in the first half of 2027. Microdosing: Szigeti et al., "Self-blinding citizen science to explore psychedelic microdosing," eLife, 2021. Go deeper - 📘 LSD: My Problem Child — Albert Hofmann's own account of discovering and researching the drug - 🌐 Search "Nutt 2010 Lancet LSD harm score" for how LSD compares to other drugs on the rigorous scale covered in this category's opening piece - 🌐 DanceSafe.org — harm-reduction information, including drug interaction warnings - 🌐 Related piece in this library: The Real Harm Ladder, this category Psilocybin: The Mushroom That's Closest to Becoming Medicine ------------------------------------------------------------ Of every substance in this category, psilocybin mushrooms may be the single closest to a mainstream medical future — with a new-drug application under rolling FDA review (as of autumn 2026), already legal for supervised use in two U.S. states with a third about to follow, and scoring the lowest of any drug in the best-known harm comparison. They're also, in the wrong setting or for the wrong person, capable of triggering a genuinely severe psychological crisis. Both of those things are true at once, and this piece covers both honestly. A very old drug, a very recent legal status Humans have almost certainly used psilocybin-containing mushrooms for thousands of years across multiple cultures, including documented ritual use in Mesoamerica. Western science identified the active compound after Swiss chemist Albert Hofmann — the same chemist behind LSD — isolated psilocybin in 1958 from mushroom samples brought back from Mexico. Like LSD, it saw a burst of legitimate psychiatric research in the 1950s and '60s, then fell under the same Schedule I ban in 1970, halting formal research for roughly three decades. The current legal and clinical picture Psilocybin is now in one of the fastest-moving positions of any drug in this category. In the United States, Oregon became the first state to legalize supervised, licensed psilocybin services in 2020, followed by Colorado in 2022; New Mexico passed a medical psilocybin law in 2025, and its program, which the state aims to open by 31 December 2026, was still in rulemaking in October 2026. Oregon's service centers have served well over 10,000 clients since opening in 2023 (the Oregon Health Authority publishes quarterly figures), and Colorado's first licensed healing centers opened in 2025. It remains Schedule I federally, which means insurance doesn't cover state-legal sessions and it's still fully illegal outside those specific state programs. On the clinical-trial side, COMPASS Pathways' psilocybin formulation (COMP360) has produced two positive Phase 3 trials for treatment-resistant depression. In April 2026 the FDA agreed to review its new-drug application on a rolling basis and awarded it a Commissioner's National Priority Voucher, which can shorten review to a month or two. As of August 2026, the company expected to finish submitting in the fourth quarter of 2026 and to launch in the first half of 2027 — if the FDA approves it and the DEA reschedules the drug. (An LSD-based drug has since reported positive Phase 3 results too, but its developer plans to apply only in 2027, so psilocybin is currently first in line; see the LSD piece.) What the risk profile actually looks like By the numbers, psilocybin mushrooms scored the lowest of all 20 drugs in the best-known published harm comparison (Nutt and colleagues, 2010, covered in this category's opening piece): 6 out of 100, just below LSD's 7, and far below alcohol (72), tobacco (26) and cannabis (20). (Several substances in this category, such as DMT and ayahuasca, weren't part of that study.) There's no evidence of physical organ damage from typical use, no established fatal overdose from psilocybin's own toxicity, and it isn't associated with the kind of physical addiction or dependence seen with opioids, alcohol, or nicotine — tolerance actually builds so fast with repeated daily use that compulsive use is largely self-limiting. That low score doesn't mean no risk. The real dangers are the same category as LSD's, and worth taking just as seriously: Psychological crisis and setting. An unsupervised, unprepared "bad trip" can be genuinely frightening and, in rare cases, contribute to accidents from impaired judgment. This is exactly why clinical and legal therapeutic models insist on a trained facilitator, a prepared setting, and integration support afterward, rather than treating the substance alone as the whole intervention. Psychosis risk in vulnerable individuals. As with LSD, a personal or family history of psychosis or schizophrenia is a serious red flag; psilocybin can trigger or unmask psychotic symptoms in people predisposed to them. Misidentification. A genuinely underrated real-world danger: foraging wild mushrooms without expert identification carries a real risk of accidentally consuming a toxic, non-psychoactive lookalike species, some of which cause severe liver damage or death. This risk has nothing to do with psilocybin's own pharmacology and everything to do with mushroom identification — a distinct hazard worth flagging on its own. Psilocybin's low toxicity score is one of the best-supported facts in this entire category. It is not the same claim as "safe under any conditions" — the setting, the support, and who's taking it still matter enormously. The benefit side: what the research actually shows Beyond the two positive Phase 3 trials for treatment-resistant depression, psilocybin-assisted therapy has shown promising results in smaller trials for end-of-life anxiety and depression in cancer patients, and for tobacco and alcohol use disorders — in each case using a small number of high-dose sessions paired with structured psychological preparation and integration, not a take-home prescription. Many participants in these trials, and many recreational users, report the experience as among the most personally meaningful of their lives — a subjective finding that researchers now take seriously as a possible mechanism, not just a side effect, of the drug's therapeutic potential. Try this If you're curious about the actual scale of the current legal shift, look up how many licensed psilocybin service centers currently operate in Oregon and Colorado combined — the number has grown fast enough that most people are surprised by how real and operational this has already become, years before any federal approval. The takeaway Psilocybin mushrooms have likely been used by humans for millennia, were scientifically isolated in 1958, banned alongside LSD in 1970, and are now further along the FDA's approval process than any other classic psychedelic — legal for supervised use in Oregon and Colorado (New Mexico's medical program is due to open by the end of 2026), with FDA approval possible in 2027. They scored the lowest of the 20 drugs in the best-known harm comparison, with very low physical toxicity and addiction potential, but carry real psychological risks — a severe crisis in the wrong setting, a serious risk in anyone predisposed to psychosis, and an entirely separate risk of misidentifying toxic lookalike mushrooms when foraging. Try this: look up current data on Oregon's and Colorado's licensed psilocybin service centers to see how far this legal shift has already gone. Sources & Further Reading Sources - Historical and cultural use, and Hofmann's 1958 isolation of psilocybin, reflect standard ethnobotanical and chemical-history documentation. - The 1970 Schedule I classification and its effect on research reflect documented U.S. drug-policy history. - State legalization status: Oregon Health Authority, Oregon Psilocybin Services data dashboard (quarterly; 1,509 clients in the first quarter of 2025 alone); New Mexico Department of Health, Center for Medical Cannabis and Psilocybin, and Source NM reporting (August 2026) on the program's rollout. - Clinical and regulatory status: Compass Pathways, second-quarter 2026 results (SEC Form 8-K, 5 August 2026) and its April 2026 announcement of FDA rolling review and a Commissioner's National Priority Voucher. - Comparative harm scoring reflects Nutt DJ, King LA, Phillips LD, "Drug harms in the UK," The Lancet, 2010. Go deeper - 🌐 Search "COMPASS Pathways psilocybin Phase 3 results" for the current clinical trial data - 🌐 DanceSafe.org — harm-reduction guidance, including mushroom misidentification risks - 🌐 Related pieces in this library: The Real Harm Ladder and LSD, this category DMT: The Shortest, Most Intense Trip There Is --------------------------------------------- Most psychedelics take effect over 30 to 90 minutes and last for hours. Smoked or vaporized DMT hits within seconds and is often entirely over within 5 to 15 minutes — a complete, often overwhelming altered state compressed into less time than a phone call. It's also one of the only psychedelics your own body already produces in trace amounts, for reasons science still doesn't fully understand. An ancient plant practice, a young laboratory discovery DMT (N,N-dimethyltryptamine) was first synthesized in a lab in 1931 by chemist Richard Manske, decades before its psychoactive properties were explored. Indigenous peoples of South America, meanwhile, had been using DMT-containing plants long before Western chemistry named the molecule. A roughly 1,000-year-old ritual bundle from a rock shelter in present-day Bolivia held traces of DMT alongside harmine (the vine compound used in ayahuasca), cocaine and other substances (Miller and colleagues, PNAS, 2019). Claims that ayahuasca itself is far older, based on small ceramic vessels from Ecuador dated to around 2400 BCE, rest on an interpretation (by the Ecuadorian scholar Plutarco Naranjo, 1986) that other researchers dispute. Formal human research on smoked or injected DMT began in the 1950s under researcher Stephen Szara, then was halted, like nearly every other psychedelic, by the wave of drug-policy restriction that began in the 1960s. Psychiatrist Rick Strassman restarted formal human DMT research at the University of New Mexico in 1990, running the first new U.S. clinical studies of a psychedelic in about two decades and popularizing the drug's nickname, "the spirit molecule," through his subsequent book. What actually happens, and why it's different from other psychedelics Taken orally, DMT is broken down almost immediately by an enzyme in the gut (monoamine oxidase) and has essentially no effect — this is precisely why ayahuasca, the traditional Amazonian brew, combines DMT-containing plant material with a separate plant containing monoamine oxidase inhibitors (MAOIs), letting the DMT survive digestion and reach the brain (covered in its own piece in this category). Smoked, vaporized, or injected, DMT bypasses digestion entirely and produces one of the fastest, most intense psychedelic experiences known — commonly described as a complete break from ordinary reality, frequently involving vivid geometric visuals and, for many users, a subjective sense of encountering another intelligence or space entirely separate from consensus reality. Whatever its ultimate explanation, that specific, consistent phenomenological report across unconnected users is one of the more genuinely strange and well-documented features of the DMT experience. The real dangers Like other classic psychedelics, DMT has low toxicity and no evidence of physical addiction — its intensity comes from the depth of the experience, not from organ damage or a buildup of physical dependence. The real risks: Overwhelming intensity with essentially no time to prepare. Because the onset is so fast and the peak so total, there's very little opportunity to "back out" or adjust once the experience begins, unlike a slower-onset drug where a user has time to reassess. This makes setting and having a sober, trusted person present especially important. Physical safety during the peak. Users are often completely non-functional for several minutes — unaware of their surroundings, sometimes losing physical coordination entirely — which makes a safe, seated or reclined position and a sober sitter a real practical safety measure, not an optional nicety. Psychosis risk in vulnerable individuals. As with other classic psychedelics, a personal or family history of psychosis is a serious contraindication. MAOI interactions. Your body's monoamine oxidase (MAO) enzymes are what keep DMT short: they make swallowed DMT inactive and break down smoked or vaporized DMT within minutes. Anything that blocks those enzymes — the harmala alkaloids in ayahuasca vine or Syrian rue, or MAOI antidepressants — makes DMT stronger and much longer-lasting, and combining an MAOI with other serotonergic drugs (such as SSRIs or MDMA) can cause dangerous serotonin syndrome. This matters most for ayahuasca (see that piece). DMT compresses the entire arc of a psychedelic experience — onset, peak, and return — into a window shorter than most people's commute. That speed is exactly what makes preparation and a safe physical setting non-negotiable rather than optional. The research picture DMT-specific clinical research is smaller and earlier-stage than the LSD or psilocybin pipelines, but growing — small trials have explored short-acting DMT and DMT analogues for depression, partly because its extremely brief duration is attractive for a clinical setting compared to psilocybin or LSD's much longer sessions. Some researchers have also proposed that endogenous DMT — the trace amounts the body naturally produces — may play a role in ordinary brain function, dreaming, or naturally occurring altered states, though this remains a genuinely open and actively debated area of neuroscience, not an established finding. Try this If you want a sense of just how compressed a DMT experience is compared to other psychedelics, compare its typical 5–15 minute smoked duration to LSD's 8–12 hours and psilocybin's 4–6 hours — the difference in scale is a big part of why the two require such different practical safety approaches. The takeaway DMT was synthesized in 1931 but has been used in plant form by South American peoples for at least a thousand years; smoked or vaporized, it produces one of the fastest and most intense altered states of any known drug, typically resolving in under 15 minutes. It carries the same low physical toxicity and addiction profile as other classic psychedelics, but its speed and intensity make physical safety during the peak experience — a safe position, a sober sitter — a genuinely important practical precaution rather than an optional one. Small early-stage clinical research is exploring its therapeutic potential, partly because its brevity is clinically convenient. Try this: compare DMT's typical duration to LSD's and psilocybin's side by side to understand why its safety considerations are genuinely different from the other classic psychedelics in this category. Sources & Further Reading Sources - DMT's 1931 synthesis and Strassman's 1990–1995 University of New Mexico studies reflect standard pharmacological history. Archaeology: Melanie J. Miller et al., "Chemical evidence for the use of multiple psychotropic plants in a 1,000-year-old ritual bundle from South America," PNAS, 2019 (Penn State and UC Berkeley news releases, 6 May 2019); the debate over Plutarco Naranjo's 1986 dating of Ecuadorian vessels is summarised by Chacruna Institute, "Fake News About Ayahuasca's Archeological Antiquity." - The oral inactivity of DMT without an MAOI, and its mechanism of action, reflect standard pharmacology. - Current DMT-analogue depression research reflects ongoing 2026 clinical-trial reporting. Go deeper - 📘 DMT: The Spirit Molecule — Rick Strassman (the researcher who restarted human DMT studies in 1994) - 🌐 DanceSafe.org — harm-reduction guidance for psychedelics - 🌐 Related pieces in this library: Ayahuasca and 5-MeO-DMT, this category — two very different plant/compound relatives of DMT 5-MeO-DMT: The Toad, the Molecule, and a Real Safety Warning ------------------------------------------------------------ Of everything in this category, 5-MeO-DMT carries one of the most specific, well-documented physical dangers — not from the psychedelic compound itself, but from where it's often sourced. This piece separates the two clearly, because conflating them gets people hurt. A synthetic 1930s discovery, wrapped in a much younger myth 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine) was first synthesized by Japanese chemists in 1936. Despite persistent popular claims of ancient ceremonial toad use, there's no credible historical or archaeological evidence supporting a long tradition of using toad secretions this way — the practice of smoking dried secretions from the Sonoran Desert toad (technically named Incilius alvarius, and often marketed under the older name Bufo alvarius) for its psychoactive effect appears to be a genuinely modern development, not an ancient indigenous practice, whatever the marketing around "toad medicine" retreats might imply. Related to DMT, but pharmacologically distinct 5-MeO-DMT is chemically related to the DMT covered in this category's previous piece, but it's a different molecule with a different, generally described as even more intense, effect profile — often described by users as involving a more complete dissolution of the sense of being a separate self, rather than the visually rich imagery more commonly associated with DMT or LSD. Like DMT, it's extremely fast-acting and short in duration when smoked or vaporized, typically resolving within 15 to 30 minutes. The real, specific danger: the toad itself Here is the warning this piece exists to give clearly: raw toad secretion is not simply "natural 5-MeO-DMT." It also contains bufadienolides — cardiac glycosides, a class of compound that acts directly on heart function and can be genuinely dangerous. This is precisely why raw toad venom should never be taken orally, and why any responsible use of the toad-derived material at all requires real precautions: a baseline ECG (heart electrical activity test) and a careful review of the person's current medications beforehand are considered non-negotiable by harm-reduction and medical sources covering this substance specifically — a level of medical screening that most people encountering "toad medicine" at an informal retreat are unlikely to actually receive. Synthetic 5-MeO-DMT, by contrast, contains only the target molecule — no bufadienolides, no cardiac risk from contaminant compounds, and precise, consistent dosing. This is exactly why every current clinical research program studying this substance uses synthetic material exclusively, never raw toad secretion. There is also a real conservation problem layered on top of the safety issue. Demand from the psychedelic tourism industry has driven over-collection and mishandling of the Sonoran Desert toad, which is now considered a species of conservation concern in parts of its range — a genuinely separate ethical cost of the raw-toad sourcing model, independent of the safety argument against it. "Natural" and "safe" are doing a lot of unearned work in how toad-derived 5-MeO-DMT gets marketed. The molecule researchers actually study for safety and efficacy is the synthetic version, precisely because raw secretion carries risks the pure compound doesn't. Other dangers, beyond the toad-specific one Setting the sourcing issue aside, 5-MeO-DMT shares the general risk profile of other fast-acting classic psychedelics: real risk of an overwhelming, disorienting experience with very little time to adjust once it begins, a serious contraindication for anyone with a personal or family history of psychosis, and the same physical-safety need for a safe position and a sober sitter during the brief but often totally incapacitating peak. It is also especially dangerous combined with MAO inhibitors, including harmala-containing brews such as ayahuasca or Syrian rue: a published case report (Sklerov and colleagues, Journal of Analytical Toxicology, 2005) describes a death after 5-MeO-DMT was taken in an ayahuasca-style preparation. What the early research shows Small studies using vaporized toad secretion in naturalistic (non-laboratory, real-world retreat) settings have reported sustained improvements in life satisfaction, mindfulness-related measures, and reductions in psychological symptoms following a single use, with the size of the benefit correlated to the intensity of the reported psychedelic experience. Larger, more rigorous trials are now testing synthetic formulations specifically for treatment-resistant depression. This is meaningfully earlier-stage research than the psilocybin or LSD pipelines — promising, but with a much smaller evidence base to date. Try this Before considering any 5-MeO-DMT experience, look specifically for whether the source is synthetic or toad-derived — the safety profile genuinely differs between the two, and it's one of the clearest, most actionable distinctions in this entire category. The takeaway 5-MeO-DMT was synthesized in 1936; the popular idea of an ancient toad-smoking tradition is a modern invention without real historical support. It's chemically related to DMT but produces an even more intense, ego-dissolving effect in an even shorter window. The single most important safety fact: raw toad secretion carries real cardiac risk from bufadienolide compounds it also contains, which is why clinical research uses only synthetic 5-MeO-DMT, and why toad sourcing also drives real ecological harm to a now-vulnerable species. Early research on the therapeutic potential is promising but considerably less developed than for psilocybin or LSD. Try this: if this substance interests you at all, learn to distinguish synthetic 5-MeO-DMT from toad-derived material before anything else — it's the single highest-leverage safety fact in this piece. Sources & Further Reading Sources - 5-MeO-DMT's 1936 synthesis and the lack of credible historical evidence for ancient toad use reflect published pharmacological and ethnobotanical history. - Bufadienolide cardiac risk and the resulting ECG/medication-screening recommendation reflect published clinical safety guidance on toad-secretion use. - Sonoran Desert toad conservation status reflects published conservation reporting on psychedelic-tourism-driven over-collection. - Naturalistic-setting research findings and current synthetic-formulation clinical trials for depression reflect current published research literature. Go deeper - 🌐 Search "5-MeO-DMT synthetic vs toad safety" for detailed harm-reduction comparisons - 🌐 DanceSafe.org — harm-reduction guidance for psychedelics - 🌐 Related piece in this library: DMT, this category, for the closely related but pharmacologically distinct molecule Ayahuasca: The Brew That Turned Chemistry Into Ceremony ------------------------------------------------------- Long before anyone had a word for "monoamine oxidase inhibitor," Amazonian peoples had already solved the precise chemistry problem it describes — combining two plants so that one protects the other's active compound from being destroyed by the human gut. That combination, refined over an unknown number of generations without any modern chemistry, is ayahuasca: one of the oldest continuously practiced psychedelic traditions on Earth, and now also a fast-growing global wellness and therapy industry. A tradition older than written record, still practiced today Some scholars have linked small ceramic vessels from Ecuador, dated to around 2400 BCE, to ayahuasca ritual, though that reading is disputed; the firmest physical evidence so far is a roughly 1,000-year-old ritual bundle from a Bolivian rock shelter containing traces of both DMT and harmine (PNAS, 2019). Indigenous Amazonian peoples across present-day Peru, Brazil, Colombia, and Ecuador have used the brew for healing and spiritual purposes for centuries, quite possibly millennia. The name refers to a decoction traditionally made by combining the Banisteriopsis caapi vine with the leaves of Psychotria viridis (or related DMT-containing plants) — the vine supplies harmala alkaloids that inhibit the gut enzyme that would otherwise instantly break down the DMT in the leaves, allowing the DMT to actually reach the brain when taken by mouth. It's a functioning pharmacological solution that Western science only later explained in molecular terms. From remote ceremony to global retreat industry For most of its history, ayahuasca use was confined to Indigenous communities and the syncretic Brazilian churches (such as Santo Daime and União do Vegetal) that incorporated it into a Christian-influenced spiritual framework starting in the early-to-mid 20th century. That changed dramatically in recent decades: by 2019, at least 232 ayahuasca retreat centers were operating across Amazonian countries and Costa Rica, with Peru hosting the most of any country, driven by a wave of international "ayahuasca tourism." The typical modern tourist is different from a traditional participant in a telling way — split roughly evenly between men and women, averaging around age 35, and, by a two-to-one margin, holding at least a university degree — a demographic profile that looks a great deal like modern Western wellness-retreat tourism generally. What the experience involves, and the real dangers An ayahuasca ceremony typically lasts several hours, guided by an experienced facilitator (traditionally a shaman, though quality and training vary enormously in the modern tourism industry), and commonly involves intense visionary experiences, deep emotional processing, and — very commonly, and considered a normal, even therapeutic part of the process — vomiting or diarrhea, sometimes called "the purge." The real risks: MAOI drug and food interactions are genuinely dangerous, not a minor caveat. Because ayahuasca contains real MAOIs, combining it with certain medications (notably SSRIs and other antidepressants, some other psychiatric medications, and certain other drugs) can cause serotonin syndrome, a potentially life-threatening reaction. Certain foods that are otherwise harmless can also cause dangerous interactions with MAOIs. This is a specific, well-documented pharmacological risk — not a vague spiritual caution — and it's the single most important safety fact in this piece. Cardiovascular strain. The intensity of the experience, combined with vomiting and purging, can be physically demanding; ceremonies are generally not advisable for people with certain heart conditions. Psychosis risk. As with other classic psychedelics, a personal or family history of psychosis is a serious contraindication — and case reports of ayahuasca-associated psychotic episodes do exist in the clinical literature, underscoring that this isn't a theoretical risk. Wildly inconsistent facilitator quality. Unlike a hospital or a research trial, a retreat center's medical screening, facilitator training, and emergency preparedness vary enormously and are largely unregulated — the growth of the tourism industry has outpaced any consistent safety standard, and a genuinely important part of "informed" use is screening the retreat itself, not just the substance. The most dangerous thing about ayahuasca usually isn't the ceremony itself — it's an unscreened medication interaction the retreat never asked about, or a facilitator with more marketing budget than actual training. What the research shows on the benefit side A growing body of research — including naturalistic studies conducted at real retreat centers rather than only in controlled labs — has found ayahuasca use associated with statistically significant reductions in depression and anxiety symptoms following a retreat, alongside a generally favorable pharmacological safety profile in screened, healthy participants. Ayahuasca and its component alkaloids are also being studied for potential benefit in substance use disorders. As with the rest of this category's psychedelics, the research base, while growing quickly, remains considerably smaller and less regulatorily advanced than psilocybin's. An honest note on cultural context Unlike most other substances in this category, ayahuasca arrives with a living Indigenous tradition attached to it, and a real, documented tension exists between that tradition and the modern global retreat industry — researchers and Indigenous advocates have raised specific concerns that many tourist-oriented "authentic" ceremonies borrow the aesthetics of Indigenous practice while disconnecting from its actual spiritual grounding, community context, and the economic benefit flowing back to source communities. Worth knowing, whatever you ultimately decide about your own interest in this substance. Try this If ayahuasca genuinely interests you, treat the medication-interaction question as non-negotiable before anything else — write out every medication and supplement you currently take and check it against a real MAOI interaction list, not a retreat center's own reassurance. The takeaway Ayahuasca combines two plants in a way that lets DMT survive digestion — a real, working pharmacological solution developed by Amazonian peoples over centuries, likely millennia, before modern chemistry could explain how it worked. It moved from Indigenous and syncretic-church use into a large global retreat tourism industry in recent decades, with quality and safety standards varying enormously between operators. Its most serious, well-documented danger is a MAOI interaction with certain medications and foods that can cause life-threatening serotonin syndrome — a specific pharmacological risk, not a vague caution. Naturalistic research shows real promise for depression and anxiety, alongside an honest, ongoing conversation about cultural appropriation in the modern tourism industry. Try this: before any ayahuasca ceremony, check every medication and supplement you take against a real MAOI interaction list — this single check matters more than almost anything else in this piece. Sources & Further Reading Sources - Historical and archaeological evidence of ayahuasca use, and its traditional plant combination and pharmacology, reflect published ethnobotanical and pharmacological research; the 1,000-year-old Bolivian bundle is Melanie J. Miller et al., PNAS, 2019, and the dispute over the 2400 BCE Ecuadorian vessels (Plutarco Naranjo, 1986) is summarised by the Chacruna Institute. - Retreat center growth statistics and tourist demographic data reflect published 2019 ayahuasca tourism research (ICEERS). - MAOI drug and food interaction risks and serotonin syndrome reflect standard clinical pharmacology and published case reports. - Naturalistic-setting depression/anxiety outcome research reflects published studies including work published in Frontiers in Psychiatry. - Cultural-appropriation concerns in the modern retreat industry reflect published academic and journalistic research on ayahuasca tourism. Go deeper - 🌐 Search "ayahuasca MAOI interaction dangerous drugs" for a full interaction list before considering any ceremony - 🌐 ICEERS.org — the International Center for Ethnobotanical Education, Research and Service, a leading independent source on ayahuasca safety and context - 🌐 Related piece in this library: DMT, this category, for the core psychoactive compound ayahuasca delivers Opium: The Plant Behind Nearly Every Opioid Story ------------------------------------------------- Every other opioid in this category — heroin, fentanyl, the prescription painkillers behind the modern overdose crisis — ultimately traces back to one plant, cultivated by humans for longer than most written history. Understanding opium itself is the foundation for understanding everything that came after it. The oldest drug story in this category The opium poppy (Papaver somniferum) was cultivated in Mesopotamia by at least 3400 BCE — the Sumerians reportedly called it the "joy plant." Ancient Egyptian and Greek medical writings both describe its use for pain and sleep; Homer's Odyssey references a substance, "nepenthe," widely believed to be opium-based. For most of human history, opium — the dried latex harvested from the poppy's seed pod — was both a genuine medical tool for pain and a recreational substance, often without a clear line between the two. Empire, addiction, and a war fought over a drug Opium's most consequential modern chapter involves China. By the 18th century, opium smoking had become a significant social problem there, driven substantially by aggressive trade from the British East India Company, which found opium (grown in British-controlled India) to be an extraordinarily profitable export. When the Chinese government moved to seriously restrict the trade, Britain responded with military force — the First Opium War (1839–1842) and Second Opium War (1856–1860) — winning both and forcing China to accept continued opium imports along with other trade concessions, a historical episode still referenced in China today as part of the "century of humiliation." In 1804, German pharmacist Friedrich Sertürner isolated morphine from opium — the first pure alkaloid ever extracted from a plant — giving medicine a far more consistent and powerful pain-relief tool than raw opium, and setting up the next century of both genuine medical progress and new addiction crises. Through the Victorian era, opium tinctures like laudanum were sold with little to no regulation, including as "soothing syrups" given directly to infants — a practice responsible for real, documented infant deaths, and a sobering reminder of how differently unregulated substances were once treated. The U.S. legal turn, and an honestly uncomfortable history In the late 19th and early 20th century United States, opium smoking became specifically associated in the public imagination with Chinese immigrant communities, and the first American anti-opium laws — starting with local ordinances in the 1870s targeting opium dens — were substantially motivated by anti-Chinese sentiment rather than purely pharmacological concern, a pattern that recurs uncomfortably often across the history of American drug policy. The Harrison Narcotics Tax Act of 1914 established the first major federal framework restricting opium and its derivatives nationally, a foundational moment for the entire modern American drug-control system. Where opium sits today Recreational opium use itself is now relatively rare compared to its far more potent derivatives, morphine and heroin — most of the plant's modern relevance is as the raw agricultural material behind legal pharmaceutical opioids (morphine, codeine, and others) and illicit heroin production. Global illicit opium cultivation has historically centered on Afghanistan and Southeast Asia's "Golden Triangle" (Myanmar, Laos, Thailand); Afghan production specifically saw a dramatic decline after the Taliban imposed a cultivation ban in 2022, reshaping global illicit opioid supply chains in ways still playing out. Nearly every opioid overdose statistic you'll read in this category's other pieces traces back to one plant that humans have been cultivating for over five thousand years — the chemistry got more powerful, but the underlying substance is ancient. The real dangers and the real medical value Opium and all its derivatives share the same core physiological risk: respiratory depression, meaning a large enough dose slows or stops breathing entirely — this is the mechanism behind essentially every opioid overdose death, whatever the specific drug. Regular use also produces real physical dependence, with a genuinely unpleasant (though, unlike alcohol or benzodiazepine withdrawal, rarely directly fatal) withdrawal syndrome. Set against that risk is opium's enormous, genuine medical legacy: morphine, its direct derivative, remains a gold-standard treatment for severe acute pain and a cornerstone of palliative and end-of-life care worldwide — pain relief that, used appropriately under medical supervision, has relieved an almost incalculable amount of human suffering. Both things are true of the same plant at once. Try this Trace the chain from opium → morphine (1804) → heroin (1874, next piece) → fentanyl (1959, later piece) in your head — each step made the drug more potent and more medically useful and more dangerous at the same time, a pattern worth noticing before reading the rest of this category. The takeaway Opium has been cultivated and used by humans for over five thousand years, sitting at the root of essentially every opioid covered in this category. Its history includes genuine medical value, an empire built partly on its trade, a war fought explicitly over the right to sell it, and American drug law shaped in part by anti-Chinese sentiment rather than pharmacology alone. Every opioid descended from it shares the same fundamental danger — respiratory depression — and the same fundamental value — genuinely effective pain relief, still foundational to modern medicine. Try this: trace the opium → morphine → heroin → fentanyl chain in your head before reading the rest of this category — each step increased both the drug's medical power and its danger together. Sources & Further Reading Sources - Ancient cultivation and use of the opium poppy reflects standard archaeological and pharmacological history documentation. - The Opium Wars and their role in Chinese-British trade history reflect standard historical documentation. - Sertürner's 1804 isolation of morphine, and Victorian-era laudanum use, reflect standard pharmacological and medical history. - U.S. anti-opium legislation's origins in anti-Chinese sentiment, and the 1914 Harrison Narcotics Tax Act, reflect documented U.S. drug-policy history. - Afghan opium cultivation trends following the 2022 Taliban ban reflect current international drug-supply reporting. Go deeper - 📘 Opium: A History — Martin Booth (a full historical account) - 🌐 Search "Harrison Narcotics Act 1914 history" for the founding legislation of U.S. federal drug policy - 🌐 Related pieces in this library: Heroin and Fentanyl, this category, for opium's two most consequential modern derivatives Heroin: Marketed as the Cure, Became the Crisis ----------------------------------------------- In 1898, the German pharmaceutical company Bayer began selling a new drug commercially under the brand name Heroin, marketed as a safer, non-addictive alternative to morphine and an effective cough suppressant. Within a decade, it was clear that the marketing had it backward. That reversal — from pharmaceutical solution to global addiction crisis, roughly a century before the exact same pattern repeated with prescription opioids — is the story of heroin. From cough medicine to Schedule I Heroin (diacetylmorphine) was first synthesized in 1874 by chemist C.R. Alder Wright, working from morphine. It wasn't commercialized until Bayer brought it to market in 1898, selling it over the counter for coughs, pain, and — genuinely, at the time — as a treatment intended to help people stop using morphine. Addiction rates climbed quickly once real-world use scaled up, and by the early 20th century the truth was unavoidable: heroin wasn't less addictive than morphine, it was more so, in part because it crosses into the brain faster. The U.S. banned it outright in 1924, and it has remained a Schedule I substance — legally classified as having no accepted medical use — ever since. A drug that keeps resurfacing in American life Heroin use has moved through American culture in identifiable waves rather than a steady baseline. It was associated with jazz-era subcultures in the mid-20th century, became a significant crisis among American soldiers during the Vietnam War in the late 1960s and early '70s, and fueled serious urban addiction and crime waves through the 1970s and '80s. Its most recent major resurgence has a specific, well-documented cause: as U.S. authorities cracked down on prescription opioid overprescribing starting around 2010, many people already physically dependent on prescription painkillers shifted to heroin — often cheaper and, at the time, more available — a genuine second wave layered directly on top of the first prescription-opioid wave, both predating the still-more-dangerous fentanyl-driven third wave covered in this category's next piece. What the drug actually does, and the core danger Heroin is a powerful opioid, converted by the body into morphine after use, producing intense euphoria alongside pain relief and sedation. Like every opioid, its core lethal risk is respiratory depression — a high enough dose slows or stops breathing. Several factors make heroin specifically dangerous beyond that baseline opioid risk: Unknown and variable purity. Illicit heroin's actual strength varies significantly between batches and dealers, with no reliable way for a user to know the real dose they're taking — a critical difference from a pharmaceutical opioid dispensed at a known, labeled strength. Fentanyl contamination. This is the single most important current fact about heroin: as of the mid-2020s, illicit fentanyl (covered in the next piece, and dramatically more potent) has contaminated much of the heroin supply, either mixed in deliberately or entirely replacing heroin while still being sold as heroin. A significant share of current heroin-labeled overdose deaths involve fentanyl, xylazine, or other adulterants the buyer never knowingly consumed. Tolerance loss after abstinence. One of the most dangerous — and least intuitive — facts about heroin: after a period of abstinence (including release from incarceration or completing a detox program), tolerance drops significantly, meaning a dose that was previously manageable can be fatal. A large share of heroin overdose deaths happen specifically in this post-abstinence window, to people who believed they were taking their "usual" amount. Needle-related infection risk. Injection drug use carries a real risk of HIV, hepatitis C, and serious bacterial infections when needles are shared or reused — a risk entirely separate from the drug's own pharmacology, and one that clean-needle access programs are specifically designed to reduce. Heroin overdose deaths in the U.S. have actually been falling in recent years — not primarily because heroin got safer, but because fentanyl has displaced much of it in the illicit supply. That's not good news; it's a different, often more dangerous problem wearing heroin's old statistics. Withdrawal, addiction, and what actually helps Heroin produces real physical dependence with regular use, and withdrawal — while excruciating (flu-like symptoms, severe muscle pain, insomnia, intense cravings) — is, unlike alcohol or benzodiazepine withdrawal, rarely directly fatal on its own in an otherwise healthy adult. What does save lives, repeatedly and measurably: naloxone (brand name Narcan), an opioid overdose reversal medication now available over the counter in the U.S. without a prescription, capable of restoring breathing within minutes when administered during an overdose; fentanyl test strips, which let a user check whether a supply is contaminated before using; and medication-assisted treatment (methadone or buprenorphine) for addiction itself, which has a substantially stronger evidence base for long-term recovery than abstinence-only approaches alone. Try this If you or anyone you know uses opioids in any form, learn where to get naloxone in your area today, before it's needed — most U.S. pharmacies now stock it over the counter, and many community health organizations distribute it for free. The takeaway Heroin was marketed in 1898 as a safer alternative to morphine and turned out to be more addictive, not less — a pattern that repeated a century later with prescription opioids. It has moved through American life in identifiable waves, with its most recent resurgence directly tied to the prescription-opioid crackdown that began around 2010. Its core danger is the same as every opioid — respiratory depression — sharpened by unknown street purity, a heroin supply now heavily contaminated with much more potent fentanyl, and a specific, deadly risk of overdose after a period of abstinence when tolerance has dropped. Naloxone, fentanyl test strips, and medication-assisted treatment are proven, practical tools that save lives. Try this: find out today where to get free naloxone in your area, whether or not you think you'll ever need it. Sources & Further Reading Sources - Heroin's 1874 synthesis, 1898 Bayer commercialization, and 1924 U.S. ban reflect standard pharmaceutical and drug-policy history. - The Vietnam-era, 1970s-80s, and 2010s heroin waves reflect documented U.S. opioid-crisis history (CDC "three waves" framework). - Fentanyl contamination of the heroin supply and its effect on overdose statistics reflect current CDC and DEA reporting. - Post-abstinence overdose risk and needle-related infection risk reflect standard clinical addiction-medicine literature. - Naloxone availability and medication-assisted treatment efficacy reflect current public-health and clinical guidance. Go deeper - 🌐 CDC.gov/overdose-prevention — current U.S. overdose data and naloxone access information - 🌐 Search "naloxone Narcan where to get free near me" for local access points - 🌐 Related pieces in this library: Opium and Fentanyl, this category Fentanyl: A Legitimate Medicine That Became the Deadliest Drug in the Supply ---------------------------------------------------------------------------- A dose of fentanyl small enough to sit on the tip of a pencil can be fatal. That single fact — extreme potency in an extremely small physical volume — is both why fentanyl is genuinely valuable in medicine and why it has become, by a wide margin, the single largest driver of overdose deaths in America today. A real medicine, developed with real medical purpose Fentanyl was synthesized in 1959 by Belgian chemist Paul Janssen, developed as a powerful synthetic opioid for use in surgical anesthesia and severe pain management. It's roughly 50 to 100 times more potent than morphine by weight, which is exactly why it remains genuinely valuable in medicine: for surgical anesthesia, for severe acute pain, and for cancer patients with pain that other opioids can't adequately control, often delivered in precisely measured patches, lozenges, or IV doses under direct medical supervision. Used this way — at a known, medically calibrated dose — fentanyl is a legitimate, important medicine. How it took over the illicit drug supply Illicit fentanyl's dominance in the U.S. drug supply is a relatively recent, specific development, generally dated to around 2013–2014 — what public health researchers call the "third wave" of the opioid crisis, following the first wave of prescription-opioid overprescribing in the 1990s and the second wave of heroin resurgence around 2010. The reason is straightforward and grim: fentanyl is far cheaper to produce than growing and processing opium poppies into heroin, and its extreme potency means a small, easily smuggled quantity can be cut into a much larger volume of counterfeit product — powerful economic incentives for dealers, with none of the cost falling on them when a batch is imprecisely mixed. Why it's so specifically dangerous The margin for error is tiny. Because an effective dose is so small, even a modest miscalculation or an unevenly mixed batch — extremely common in illicit production, which has none of pharmaceutical manufacturing's precision — can mean the difference between an intended dose and a fatal one. It's routinely present in drugs sold as something else entirely. This is the single most important fact in this piece: fentanyl now regularly appears in counterfeit pills pressed to look identical to real prescription medications (fake oxycodone, fake Xanax, fake Adderall), and in cocaine, methamphetamine, and heroin, often without the buyer's knowledge. A significant share of fentanyl deaths involve people who believed they were taking a different drug entirely, or a lower dose than what was actually present. The supply keeps getting more dangerous, not less. As authorities have cracked down on fentanyl itself, adulterants have shifted to fill the gap — xylazine ("tranq"), a veterinary sedative, became widespread starting around 2022, and more recently medetomidine, another veterinary sedative, has surged dramatically: reports of it in drug seizures rose roughly 950% from 2023 to 2024 (247 to 2,616), then another 215% in 2025 (to 8,233), and in late 2025 it turned up in about a third of opioid-positive samples at half of the CDC's testing sites, almost always mixed with fentanyl rather than replacing it. Naloxone doesn't fully work on these newer adulterants. Naloxone reliably reverses fentanyl's opioid effects, but it does nothing for xylazine's or medetomidine's sedative effects — meaning a fentanyl-xylazine or fentanyl-medetomidine overdose can remain life-threatening even after naloxone is administered, which is exactly why calling emergency services during any suspected overdose remains essential, not optional, even if naloxone is used. Fentanyl didn't just make the drug supply more dangerous — it made "I know what I'm taking" a much harder claim for anyone to honestly make, for almost any illicit drug, not just opioids. An honest note on the actual trend It's worth saying plainly: overdose deaths in the U.S. have been falling substantially in recent years — roughly a 14% decline in 2025 alone, continuing a broader multi-year drop that includes the largest single-year decline on record. The causes are genuinely debated (wider naloxone access, fentanyl test strip availability, better overdose education, and some argue a grim demographic factor of the most vulnerable users having already died), but the trend itself is real and worth knowing, alongside the ongoing danger from newer adulterants. What actually helps Fentanyl test strips let a user check any substance — pills, powder, or otherwise — for fentanyl's presence before using, and are legal harm-reduction tools in a growing number of U.S. states. Naloxone, now available over the counter, remains the single most important overdose-reversal tool available, even with its limits against newer sedative adulterants — administer it, and call emergency services, every time. Never using alone is one of the single most effective things anyone can do to survive an overdose, since someone else present is what makes rescue possible at all. Try this If you or someone you know uses any illicit drug — not just opioids — get fentanyl test strips and learn how to use them; cross-contamination now runs across drug categories, not just within the opioid supply. The takeaway Fentanyl is a real, medically valuable synthetic opioid, roughly 50–100 times more potent than morphine, that became the dominant driver of U.S. overdose deaths after entering the illicit drug supply around 2013–2014 — cheap to produce, easy to smuggle, and devastatingly easy to miscalculate. It's now routinely found in counterfeit pills and other drugs without buyers' knowledge, and the illicit supply has grown even more dangerous with the rapid rise of veterinary sedative adulterants like xylazine and medetomidine, which naloxone doesn't reverse. Overdose deaths have fallen substantially in the past couple of years, a genuinely positive trend worth knowing alongside the ongoing risk. Try this: if you or anyone you know uses any illicit drug, get fentanyl test strips — contamination now crosses drug categories, not just within opioids. Sources & Further Reading Sources - Fentanyl's 1959 synthesis and legitimate medical use reflect standard pharmacological history. - The "third wave" opioid-crisis framework and fentanyl's entry into the illicit supply around 2013–2014 reflect CDC and DEA documented history. - Medetomidine figures: CDC Health Alert Network advisory HAN-00527 (April 2026), using National Forensic Laboratory Information System seizure data. Xylazine history reflects DEA public-health reporting. - Naloxone's limitations against sedative adulterants reflect current clinical and public-health guidance. - Overall U.S. overdose deaths: CDC National Center for Health Statistics provisional data, 13 May 2026 (an estimated 69,973 deaths in 2025, down from 81,313 in 2024). Go deeper - 🌐 DEA.gov — official alerts on fentanyl and adulterant threats - 🌐 Search "fentanyl test strips legal my state" for current local access and legality - 🌐 Related pieces in this library: Opium and Heroin, this category Benzodiazepines: The Pills That Are Dangerous Mainly in Combination ------------------------------------------------------------------- Unlike most other substances in this category, benzodiazepines are usually prescribed by an actual doctor, taken exactly as directed, and still capable of producing real physical dependence within weeks. Their story is less about a dramatic underground history and more about a quiet, extremely common risk hiding inside completely ordinary medical use. From "miracle drug" to controlled substance in fifteen years The first benzodiazepine, chlordiazepoxide (Librium), was introduced in 1960, followed quickly by diazepam (Valium) in 1963. Both were marketed — and initially celebrated — as a dramatically safer alternative to the barbiturate sedatives that came before them, which carried a much higher overdose risk. Benzodiazepines became genuinely enormous: Valium was the best-selling pharmaceutical in the United States for years running through the 1970s, culturally significant enough that the Rolling Stones' 1966 song "Mother's Little Helper," about a suburban housewife relying on "a little yellow pill" to get through her day, is widely taken to be about tranquillizers like it (the song never names the drug). By 1975, doctors and regulators had recognized what the barbiturate comparison had obscured: benzodiazepines could also cause dependence and misuse, and that year the U.S. placed them in Schedule IV of the Controlled Substances Act. The familiar advice to limit use to two to four weeks came later and from Britain: in 1988 the UK's Committee on Safety of Medicines advised that benzodiazepines be used only for short-term relief (two to four weeks) of severe anxiety or insomnia. In 2020 the FDA added a boxed warning about abuse, dependence and withdrawal. That short-term guidance is still routinely exceeded in real-world prescribing today. What they're actually for, and why they're genuinely useful The most commonly prescribed benzodiazepines today include alprazolam (Xanax), diazepam (Valium), clonazepam (Klonopin), and lorazepam (Ativan), used to treat anxiety and panic disorders, seizures, insomnia, and muscle spasms. One specific use deserves particular mention: benzodiazepines are the standard, genuinely life-saving medical treatment for severe alcohol withdrawal, which — unlike opioid withdrawal — can itself be fatal without proper medical management; this is a case where the drug's calming, sedating mechanism is directly treating another drug's most dangerous withdrawal syndrome, not just masking discomfort. The dependence problem hiding inside normal use Here's the fact most people taking benzodiazepines as prescribed don't fully appreciate: physical dependence can develop within weeks, even at a normal, medically appropriate dose taken exactly as directed — this isn't primarily a story about misuse or abuse, though both happen. Once dependence sets in, stopping suddenly can trigger seizures, a genuinely dangerous withdrawal effect that puts benzodiazepines in a small, serious category (shared with alcohol) where withdrawal itself can be medically dangerous, unlike the withdrawal from opioids or stimulants. This is exactly why benzodiazepine discontinuation is supposed to involve a slow, medically supervised taper, never an abrupt stop. The real danger: combination, not the drug alone Taken by itself, a benzodiazepine overdose in an otherwise healthy adult is rarely fatal — this genuinely distinguishes benzodiazepines from opioids, where overdose risk from the drug alone is the central danger. The real, well-documented danger is combination: benzodiazepines depress the central nervous system, and combining them with other depressants — opioids or alcohol especially — compounds that depression in a way that becomes genuinely lethal far more easily than either substance alone. More than nine in ten deaths that involve a benzodiazepine also involve an opioid (92.7% in the CDC's 2021 analysis of 23 U.S. states, January–June 2020, two-thirds with illicit fentanyl); benzodiazepines are only rarely the sole cause of an overdose death, but they're a dramatic multiplier of risk when combined with something else. Benzodiazepines flip the usual overdose story: the drug that's relatively safe by itself becomes one of the most dangerous combination risks in the entire category, specifically because it's so often prescribed alongside — or used recreationally alongside — something else. What this means practically If you're prescribed a benzodiazepine, the single most important practical facts are: don't combine it with alcohol or opioids without your prescriber's explicit knowledge and guidance, don't stop taking it abruptly after regular use without medical supervision, and use it for the shortest effective duration your doctor recommends rather than as an indefinite daily habit, given how quickly dependence can build even at a normal dose. Try this If you or someone you know takes a benzodiazepine regularly, check today whether a tapering plan exists for eventually stopping it — many long-term users never discussed one with their prescriber, and having the conversation before it's urgently needed is far safer than an abrupt stop later. The takeaway Benzodiazepines, introduced in 1960 as a safer alternative to barbiturates, became enormously popular before their real addiction potential was recognized by the mid-1970s. They remain genuinely useful — including as the standard medical treatment for dangerous alcohol withdrawal — but can produce real physical dependence within weeks of normal use, and abrupt discontinuation after dependence sets in can cause seizures. Taken alone, overdose is rarely fatal in a healthy adult; the real, well-documented danger is combining them with opioids or alcohol; in recent U.S. data, more than nine in ten benzodiazepine-involved deaths also involved an opioid. Try this: if you take a benzodiazepine regularly, ask your prescriber today whether a tapering plan exists — don't wait until stopping becomes urgent. Sources & Further Reading Sources - Benzodiazepine introduction history (Librium 1960, Valium 1963), cultural prominence, and 1975 Schedule IV classification reflect standard pharmaceutical and drug-policy history. The two-to-four-week limit: UK Committee on Safety of Medicines, Current Problems no. 21 (January 1988). FDA Drug Safety Communication, "FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class" (23 September 2020). - Opioid co-involvement: Liu S, et al., "Trends in Nonfatal and Fatal Overdoses Involving Benzodiazepines — 38 States and the District of Columbia, 2019–2020," CDC MMWR 70(34), August 2021. Physical dependence timelines and withdrawal seizure risk reflect published clinical addiction-medicine literature. - Benzodiazepines' role in medically managing severe alcohol withdrawal reflects standard clinical guidance. Go deeper - 🌐 Search "benzodiazepine tapering guidelines" for information on safe discontinuation - 🌐 CDC.gov/overdose-prevention — current data on combination overdose risk - 🌐 Related piece in this library: Alcohol, this category, for the withdrawal syndrome benzodiazepines are used to treat Alcohol: The Drug We Don't Call a Drug -------------------------------------- If alcohol were discovered today and someone proposed selling it at every grocery store, gas station, and restaurant in the country, it would almost certainly never be approved — it's addictive, it causes cancer, and on the single most rigorous published harm-comparison study available (covered in this category's opening piece), it scored as more harmful, combining damage to the user and to everyone around them, than heroin or crack cocaine. It's also the oldest, most culturally embedded drug on Earth, deeply woven into religion, celebration, and daily life for most of recorded human history. Both of those facts are true, and neither cancels the other out. Older than written history Fermentation happens naturally whenever sugar-containing liquid sits exposed to wild yeast, so alcohol's origins likely predate deliberate agriculture — pottery residue from Jiahu, China, shows evidence of a fermented rice, honey, and fruit beverage dating back roughly 9,000 years, among the oldest confirmed alcoholic beverages known. Beer was central to daily diet, religious ritual, and even currency in ancient Mesopotamia and Egypt; wine held comparable cultural weight in ancient Greece and Rome, where it was central to religious worship (Dionysus, later Bacchus) as much as to ordinary meals. Distillation — producing much stronger spirits than fermentation alone can — spread through the medieval Islamic world and Europe; the English word "alcohol" itself descends from the Arabic al-kuhl. The one time America tried banning it outright The United States ran history's largest real-world experiment in alcohol prohibition: the 18th Amendment and the Volstead Act banned the manufacture, sale, and transport of alcoholic beverages nationally from 1920 to 1933. The result is a well-documented case study in how prohibition can reshape a substance's risk profile without eliminating its use — rather than stopping drinking, it drove the trade underground, fueled the rise of organized crime (Al Capone's bootlegging empire being the most famous example), and made the alcohol that was available considerably less consistent in quality and strength, contributing to real poisoning incidents from unregulated production. Public support collapsed as the Great Depression deepened, and the 21st Amendment repealed Prohibition in 1933 — the only time in U.S. history a constitutional amendment has been fully reversed. What the current evidence actually shows For decades, a widely repeated public message held that moderate drinking — particularly red wine — might offer real heart-health benefits. That claim has not held up well under more rigorous scrutiny. Much of the original supporting research had a structural flaw: it often compared moderate drinkers to all non-drinkers, a group that includes people who quit drinking specifically because they were already sick — a confound that made moderate drinking look protective when it likely wasn't. A major study commissioned by the U.S. government and published in June 2026 in the Journal of Studies on Alcohol and Drugs (the Alcohol Intake and Health Study) found no level of drinking with a net health benefit, and calculated that risks of alcohol-caused death climb from about a drink a day. The World Health Organization counts alcohol as a causal factor in more than 200 disease and injury conditions, including at least seven types of cancer. Not every review agrees on the details: a 2024 National Academies review still found moderate drinkers had slightly lower death rates from all causes than people who never drank, though it rated that evidence low-certainty and found higher breast cancer risk. In January 2026, U.S. federal dietary guidelines shifted away from specific per-occasion drink limits toward the more general, and notably more cautious, recommendation to simply "consume less for better health." The direction of the evidence has moved: the WHO's position (stated in 2023) is that no level of drinking is safe for health, and as of 2026 no amount of alcohol has been shown to be fully safe. The "a glass of red wine a day is good for your heart" claim that shaped public health messaging for a generation turns out to have been largely a statistical artifact. That's a genuinely important, still under-appreciated update. The real dangers, beyond the headline cancer risk Withdrawal can be fatal. Unlike most drugs in this category, alcohol withdrawal in a person with significant physical dependence can cause seizures and a life-threatening condition called delirium tremens — this is precisely why medical supervision (often involving the benzodiazepines covered in this category's previous piece) is genuinely necessary for someone stopping heavy, long-term drinking, not merely advisable. Accidents and violence. A large share of alcohol's total measured harm in the rigorous 2010 comparison study came specifically from harm to others, not just the drinker — drunk driving deaths, alcohol-involved violence, and family and community damage, which is a major reason it scored so high overall despite being legal. Pregnancy. No amount of alcohol has been established as safe during pregnancy; fetal alcohol spectrum disorders are a real, entirely preventable cause of lifelong developmental harm. Liver disease and addiction. Regular heavy use causes real, sometimes irreversible liver damage (fatty liver, hepatitis, cirrhosis), and alcohol use disorder is a genuine, common addiction — not simply a matter of willpower, and one of the few addictions in this category where medically supervised detox is a real safety requirement, not just a comfort measure. What's genuinely real on the other side Setting health claims aside, alcohol's social and cultural role is real and shouldn't be dismissed as pure liability: it's deeply integrated into religious practice across multiple traditions (wine in Christian communion, kiddush in Jewish practice, and others), functions as a widely used, culturally sanctioned social lubricant, and provides genuine, if modest, relaxation and enjoyment for a large share of people who drink moderately and without dependence. None of that changes the current honest health verdict — but it's a real part of why this drug occupies such a different cultural position than everything else in this category, despite scoring as it does on rigorous harm measures. Try this Next time you see "moderate drinking" described as heart-healthy, check the publication date of the source — if it predates roughly 2018, it's very likely relying on the older, now-contested comparison methodology this piece describes. The takeaway Alcohol is likely the oldest drug in continuous human use, deeply woven into culture and religion for thousands of years — and, by the most rigorous published harm-comparison study available, the single most harmful drug once damage to others is included, ahead of heroin and crack cocaine. The long-standing belief that moderate drinking offers real health benefits has not held up under more rigorous research, including a 2026 U.S. study that found no level of drinking with a net health benefit; the WHO links alcohol to over 200 diseases and injuries, including at least seven cancers. Its real dangers extend beyond the drinker to drunk driving and violence, and its withdrawal, unlike most other drugs in this category, can be genuinely fatal without medical supervision. Try this: check the publication date next time you encounter a claim that moderate drinking is good for your heart — sources before roughly 2018 are very likely relying on now-contested methodology. Sources & Further Reading Sources - Early fermentation and cultural history reflect archaeological research (including Jiahu, China pottery residue analysis) and standard historical documentation. - U.S. Prohibition history (1920–1933) reflects standard documented U.S. history. - Current alcohol health research reflects the Alcohol Intake and Health Study (Journal of Studies on Alcohol and Drugs, 9 June 2026; coverage by CNN and the Public Health Institute), the National Academies' Review of Evidence on Alcohol and Health (December 2024), the WHO statement "No level of alcohol consumption is safe for our health" (Lancet Public Health, January 2023), and the January 2026 U.S. HHS/USDA dietary guidelines. - WHO alcohol-cancer classification reflects World Health Organization published carcinogen classifications. - Comparative harm scoring reflects Nutt DJ, King LA, Phillips LD, "Drug harms in the UK," The Lancet, 2010. - Alcohol withdrawal and delirium tremens risk reflect standard clinical addiction-medicine literature. Go deeper - 🌐 Search "Alcohol Intake and Health Study 2026 Journal of Studies on Alcohol and Drugs" for the full study behind this piece's central health claims - 🌐 WHO.int — World Health Organization guidance on alcohol and cancer risk - 🌐 Related pieces in this library: The Real Harm Ladder and Benzodiazepines, this category Cocaine: From Sacred Leaf to Cartel Wars ---------------------------------------- Sigmund Freud didn't just use cocaine recreationally — he wrote a scientific paper promoting it, "Über Coca" (1884), genuinely believing he'd found a wonder drug for depression, fatigue, and morphine addiction, before watching a close friend he'd recommended it to spiral into severe addiction. That arc — genuine enthusiasm, real harm, slow public reckoning — repeats throughout cocaine's history, right up to the present overdose crisis. From an Andean staple to a Victorian wonder drug Indigenous peoples of the Andes have chewed coca leaves for roughly 8,000 years — a mild, traditional stimulant practice, pharmacologically quite different from refined cocaine, that remains legal and culturally normal in parts of South America today. German chemist Albert Niemann isolated pure cocaine from the leaf in 1859, and the drug entered a genuine wonder-drug era in the late 19th century: Vin Mariani, a coca-infused wine, was endorsed by public figures including Pope Leo XIII, and the original 1886 formula for Coca-Cola contained coca leaf extract (the cocaine content was removed by 1903, though a specially processed, decocainized coca leaf extract is reportedly still used for flavoring today). The Harrison Narcotics Tax Act of 1914 — the same law that restricted opium — brought this open era to a close. Two very different popularity waves, one honest omission Powder cocaine resurged sharply in the U.S. in the 1970s and became strongly associated with 1980s disco and Wall Street culture — an expensive drug with a glamorous public image, fed by a dramatic increase in supply from Colombian, Bolivian, and Peruvian cartels, most infamously Pablo Escobar's Medellín Cartel, which at its peak reportedly profited roughly $4 billion a year. Crack cocaine — a cheaper, smokable, crystallized form developed during this same boom — spread rapidly starting in the mid-1980s, hitting low-income urban communities, disproportionately Black communities, especially hard. The legal response to these two forms of the same drug was strikingly unequal, and it's worth stating plainly: 1986 U.S. federal law punished crack cocaine offenses 100 times more harshly than equivalent powder cocaine offenses — meaning five grams of crack triggered the same mandatory minimum sentence as 500 grams of powder — despite both being the same drug in different physical forms. That disparity, widely criticized as effectively racialized in its impact, wasn't reduced (to a still-unequal 18:1 ratio) until the Fair Sentencing Act of 2010. What the drug actually does, and the real dangers Cocaine is a powerful stimulant, working primarily by blocking the reuptake of dopamine and other neurotransmitters, producing intense euphoria, energy, and confidence, typically for a relatively short duration (30–90 minutes depending on method), which itself drives a pattern of repeated redosing. Cardiovascular risk is the core danger, at any dose. Unlike opioids, where the primary lethal mechanism is respiratory depression, cocaine's primary danger is cardiac: it constricts blood vessels and increases heart rate and blood pressure, creating real risk of heart attack, stroke, or fatal arrhythmia — including in young, otherwise healthy users with no prior heart condition, and even on a single use, not only with chronic heavy use. Fentanyl contamination has become the dominant current risk. This is the single most important current fact about cocaine: roughly 79% of cocaine-involved overdose deaths now also involve an opioid, overwhelmingly illicit fentanyl — meaning a large share of "cocaine deaths" are really fentanyl deaths in a supply the user never knowingly chose to mix. Cocaine-involved overdose deaths overall have more than quadrupled since 2015, driven substantially by this contamination rather than cocaine's own toxicity alone. Addiction potential is real and severe, though, notably, physical withdrawal from cocaine is generally not medically dangerous the way alcohol or benzodiazepine withdrawal can be — the risk is intense psychological craving and relapse, not a dangerous physical withdrawal syndrome. Route-specific damage. Regular snorting can cause serious, sometimes permanent damage to the nasal septum; smoking crack delivers the drug to the brain even faster than snorting, intensifying both the high and the addiction risk. Cocaine's overdose story has quietly changed. It used to be almost entirely about the drug's own cardiac effects. Today, a large share of cocaine deaths are actually fentanyl deaths, happening to people who thought they were only using cocaine. Is there a benefit case here? Unlike several other substances in this category, cocaine doesn't have a meaningful modern therapeutic research renaissance behind it — there's no serious clinical pipeline exploring cocaine itself as a treatment for anything. Its one narrow legitimate medical use today is as a topical local anesthetic in certain ear, nose, and throat surgical procedures, valued there for its combination of numbing and blood-vessel-constricting effects — a real but very limited medical role, nothing like the broader psychiatric research happening with the psychedelics covered elsewhere in this category. Try this If you or anyone you know uses cocaine, get fentanyl test strips — given that nearly 4 in 5 cocaine overdose deaths now involve an opioid, this is one of the single highest-leverage harm-reduction steps available for this specific drug. The takeaway Cocaine has a genuinely ancient legitimate use as chewed coca leaf, alongside a modern history running from Victorian wonder drug through 1980s glamour culture to the devastating, racially disparate legal response to crack cocaine specifically. Its core danger is cardiovascular — heart attack, stroke, or fatal arrhythmia, possible even on a single use — and its dominant current danger is fentanyl contamination, now present in roughly 4 out of 5 cocaine-involved overdose deaths. Unlike several drugs in this category, it carries no significant modern therapeutic research case; its one legitimate medical role is narrow, as a surgical local anesthetic. Try this: get fentanyl test strips if you or anyone you know uses cocaine — nearly 80% of current cocaine overdose deaths involve an opioid the user didn't necessarily know was there. Sources & Further Reading Sources - Traditional Andean coca use, Niemann's 1859 isolation, and the Victorian wonder-drug era (including Coca-Cola's original formula) reflect standard pharmacological and historical documentation. - Freud's cocaine advocacy and "Über Coca" reflect documented biographical history. - The 1980s crack epidemic and the 100:1 federal sentencing disparity (reduced to 18:1 by the 2010 Fair Sentencing Act) reflect documented U.S. drug-policy and legal history. - Current cocaine use, overdose, and fentanyl co-involvement statistics reflect current 2026 U.S. federal substance-use survey and overdose-mortality reporting. - Cardiovascular mechanism and risk reflect standard clinical pharmacology. Go deeper - 🌐 Search "crack vs powder cocaine sentencing disparity history" for the full legal-history context - 🌐 DanceSafe.org — fentanyl test strip access and harm-reduction guidance - 🌐 Related pieces in this library: Fentanyl and The Real Harm Ladder, this category Methamphetamine: The Wartime Stimulant That Never Really Left ------------------------------------------------------------- During World War II, Nazi Germany distributed methamphetamine to soldiers and factory workers under the brand name Pervitin to fight fatigue and boost alertness — and German forces weren't unique in this; multiple militaries, including Japan's and, to a lesser extent, the Allies, used amphetamine-type stimulants during the war for the same purpose. A drug developed for wartime endurance went on to shape drug policy, rural American life, and a still-unfolding public health crisis, in ways that have almost nothing to do with its original purpose. From chemistry curiosity to wartime staple Amphetamine was first synthesized in 1887; methamphetamine, the more potent, faster-acting relative, followed in 1893 and was refined into its crystalline smokable form in 1919 by Japanese chemist Akira Ogata. Its wartime use across multiple countries in the 1940s set up the first real epidemic: after the war, large military stockpiles of methamphetamine entered the civilian market in Japan, triggering that country's first documented meth epidemic in the 1950s. In the U.S., meth and related amphetamines were legally prescribed through the 1950s and '60s for weight loss, depression, and fatigue — a legitimate medical framing that, in hindsight, undersold the drug's addiction potential considerably. Bikers, rural labs, and a law that actually worked — for a while Meth production and distribution in the U.S. became associated with outlaw motorcycle clubs from the 1960s through the 1980s (sometimes called "crank" from its early smuggling method), then shifted dramatically in the 1990s and 2000s toward small-scale rural production — the "meth lab" era that became a defining, if stereotyped, image of the rural Midwest drug crisis and later a cultural touchstone through shows like Breaking Bad. This particular form of the problem had an identifiable choke point: small-batch domestic production relied heavily on pseudoephedrine, a common over-the-counter decongestant ingredient. The Combat Methamphetamine Epidemic Act of 2005, which restricted retail pseudoephedrine sales, substantially cut domestic small-lab production — a genuinely rare example of a specific drug-policy intervention producing a measurable, specific result. The supply shifted, not the demand Restricting the precursor chemical didn't end meth's presence — it moved production overseas and to large-scale, cartel-run industrial operations, mostly in Mexico, capable of producing meth more cheaply, more potently, and more consistently than the old small domestic labs ever could. Combined with the ongoing opioid crisis, researchers now describe the current landscape as a "fourth wave" of America's overlapping drug crises, driven substantially by stimulants (meth and cocaine) alongside opioids rather than opioids alone. Roughly 2 million U.S. adults reported past-year methamphetamine use recently — up 43% from four years earlier — even as overall overdose numbers (including a modest recent decline in psychostimulant-involved deaths specifically) have started to improve. What the drug actually does, and the real dangers Methamphetamine is a powerful, long-acting stimulant — effects from a single dose can last many hours longer than cocaine's, driving longer binges and more profound sleep deprivation. The real dangers: Severe cardiovascular strain. Like cocaine, meth significantly raises heart rate and blood pressure and constricts blood vessels, creating real risk of heart attack, stroke, and, with chronic heavy use, lasting cardiovascular damage. Meth-induced psychosis. Heavy or prolonged use is strongly associated with a genuine psychotic state — paranoia, hallucinations, delusions — that can persist for weeks after use stops, and in some cases longer, distinct from and generally more severe and longer-lasting than the psychosis risk associated with the psychedelics covered elsewhere in this category. "Meth mouth." The severe dental damage associated with chronic meth use is real and well-documented, though it's an indirect effect rather than a direct chemical attack on teeth: it results from the combination of dry mouth (reduced saliva, which normally protects teeth), teeth grinding, poor oral hygiene during binges, and frequent consumption of sugary drinks to combat dry mouth — a cluster of behavioral and physiological effects that together cause rapid, severe tooth decay. Profound addiction potential and cognitive effects. Meth is strongly and rapidly addictive, and chronic heavy use is associated with real, measurable cognitive impairment, alongside extreme weight loss and compulsive skin-picking (a common symptom of meth-associated formication, the sensation of insects crawling under the skin). Fentanyl cross-contamination. As with cocaine, illicit methamphetamine can be contaminated with fentanyl, adding a genuine opioid overdose risk to a drug whose users may have no history with or tolerance for opioids at all. The 2005 pseudoephedrine law is one of the few clean success stories in American drug policy — and also a clear lesson in how supply-side restrictions reshape a market rather than eliminate it, since industrial cartel production simply replaced the small domestic labs it shut down. Try this If methamphetamine touches your life or someone else's, know that meth-induced psychosis, while frightening, is generally treatable and often resolves with abstinence and medical support — it's a genuine psychiatric emergency worth treating as one, not a permanent condition to assume is untreatable. The takeaway Methamphetamine, refined into its modern form in 1919 and used by multiple militaries during World War II to fight fatigue, moved from legitimate 1950s-60s medical prescribing into a series of distinct American drug crises — biker-associated distribution, the rural "meth lab" era, and today's cartel-supplied "fourth wave," now intertwined with the broader opioid crisis and its own fentanyl contamination risk. A 2005 law restricting a key precursor chemical genuinely cut domestic small-lab production, but overseas industrial production simply replaced it. Its core dangers are severe cardiovascular strain, meth-induced psychosis that can persist for weeks, "meth mouth" from a cluster of indirect physiological effects, and profound addiction potential. Try this: if meth-induced psychosis affects someone you know, treat it as the genuine, generally treatable psychiatric emergency it is — not an assumed-permanent condition. Sources & Further Reading Sources - WWII-era military stimulant use (including Pervitin) and postwar Japanese epidemic history reflect documented pharmacological and military history. - U.S. meth production history, including the biker-distribution era and rural lab era, and the 2005 Combat Methamphetamine Epidemic Act's effect on domestic production, reflect documented U.S. drug-policy history. - The "fourth wave" framing and current use statistics reflect current 2026 public-health and addiction-research reporting. - Meth-induced psychosis, cardiovascular risk, and "meth mouth" mechanisms reflect standard clinical and dental literature. Go deeper - 🌐 Search "Combat Methamphetamine Epidemic Act 2005 effects" for the specific policy case study - 🌐 SAMHSA.gov — treatment resources for stimulant use disorder - 🌐 Related piece in this library: Cocaine, this category, for the closest pharmacological comparison MDMA: The Drug That Was a Therapy Tool Before It Was a Party Drug ----------------------------------------------------------------- Most drugs follow a predictable order: recreational use first, therapeutic interest (if any) years or decades later. MDMA ran the sequence backward. Therapists were quietly using it to help patients open up emotionally in the late 1970s, entirely legally, years before it became a recreational phenomenon — and its journey back toward legitimate medicine has been one of the more dramatic, still-unresolved regulatory stories in this entire category. Synthesized once, rediscovered decades later MDMA (3,4-methylenedioxymethamphetamine) was first synthesized by chemist Anton Köllisch at the pharmaceutical company Merck in 1912 — the specific reason it was made and whether it was seriously explored at the time remains genuinely unclear from surviving records, and the popular claim that it was designed as an appetite suppressant is disputed rather than confirmed. It sat largely unexamined for over sixty years until Alexander "Sasha" Shulgin, an influential chemist, resynthesized it in the 1970s and introduced it to psychotherapist Leo Zeff. Zeff was reportedly convinced enough by its effects to come out of retirement, going on to introduce MDMA — legally, since it wasn't yet scheduled — to hundreds of other therapists over the following years, who used it, entirely outside any formal clinical trial structure, as an aid to opening emotional communication in individual and couples therapy. From therapist's tool to Schedule I in under a decade That quiet clinical use didn't stay quiet. By the mid-1980s, MDMA had become a recreational phenomenon under the name "Ecstasy," and the DEA moved to schedule it in 1985 specifically to curb its spreading recreational use — placing it in Schedule I, the same category as heroin, and legally ending the informal therapeutic practice that had been happening in parallel. Recreational use exploded alongside the global rave and EDM scene from the late 1980s through the 2000s, cementing its cultural identity as a nightlife drug for a generation of users who mostly had no idea it had started its modern life inside a therapist's office. The long road back to the FDA Research into MDMA-assisted psychotherapy for PTSD resumed in the early 2000s, championed for decades by the nonprofit MAPS (Multidisciplinary Association for Psychedelic Studies). Between 2004 and 2017, six Phase 2 trials showed significant reductions in PTSD symptoms among participants, and the FDA granted the treatment Breakthrough Therapy designation — a strong signal of regulatory confidence. Then, in August 2024, the FDA formally rejected the New Drug Application, following an advisory committee vote against approval that cited concerns about study design (including the practical difficulty of a genuinely "blinded" trial when participants can often tell whether they received MDMA or a placebo based on its effects alone) and cardiovascular safety data. In August 2026 the trade outlet Psychedelic Alpha reported that the therapy's developer — Lykos Therapeutics, renamed Resilient Pharmaceuticals in 2025 — had resubmitted the application without running a new Phase 3 trial, two years after the initial rejection; the company had not publicly confirmed it, and the outcome is still genuinely pending. MDMA-assisted therapy has the most extensive real clinical trial history of any drug in this category's "still seeking approval" group — and also the most cautionary tale about how much rides on trial design, not just whether a drug works. What the drug actually does, and the real dangers MDMA produces a distinctive combination of stimulant energy and strong feelings of emotional openness, empathy, and closeness to others — the specific combination that made it attractive to therapists is largely the same combination that made it attractive to ravers. Overheating is the classic rave-context danger — and the standard advice around it is more nuanced than "drink water." MDMA increases body temperature and, combined with intense dancing in hot, crowded spaces, can cause dangerous hyperthermia. But the common harm-reduction slogan oversimplifies the fix: some MDMA-related deaths have resulted specifically from drinking too much water in a short period, causing a dangerous drop in blood sodium (hyponatremia) rather than dehydration. The actual guidance from harm-reduction organizations is moderate fluid intake (sipping roughly a pint, about 500 ml, per hour while dancing and less while resting; the UK's FRANK service advises not drinking more than that), regular cooling breaks, and never chugging large volumes of water at once. Serotonin syndrome risk with certain combinations. MDMA affects serotonin directly, and combining it with SSRIs, MAOIs, or other serotonergic medications and drugs (including the ayahuasca covered earlier in this category) carries a real risk of serotonin syndrome, a potentially dangerous reaction. Adulteration is the single biggest real-world risk today. Illicit "Molly" or "Ecstasy" sold on the street or at events frequently contains little or no actual MDMA — synthetic cathinones ("bath salts"), methamphetamine, and increasingly fentanyl have all been found in products sold as MDMA, since illicit production has no quality control whatsoever. This is arguably the most important practical fact in this piece: a substantial share of "MDMA" harm is actually harm from an entirely different, unlabeled substance. Neurotoxicity concerns are real but were significantly overstated in 1990s-2000s media coverage. Some research has raised legitimate questions about serotonergic effects from heavy, frequent use, but the more alarmist "Ecstasy causes holes in your brain" framing common in earlier public messaging oversold the certainty and severity of the evidence available. The honest current position: heavy, frequent use likely carries some real risk to serotonergic function; occasional, moderate use in tested, unadulterated form appears to carry substantially less. Not classically physically addictive, but tolerance builds fast. Repeated use in close succession rapidly diminishes MDMA's characteristic effects — a pattern Shulgin himself documented — which naturally discourages frequent redosing, though psychological dependence patterns can still develop. Try this If you or anyone you know uses MDMA recreationally, get it tested first — reagent test kits and services (including organizations like DanceSafe, which also operates at many festivals) can identify whether a substance is actually MDMA or something else entirely, which current evidence suggests is the single largest real-world risk factor. The takeaway MDMA was synthesized in 1912, then quietly used by therapists to aid emotional communication in the late 1970s and early '80s — legally, before recreational use exploded and led to its 1985 Schedule I classification. Its return toward FDA approval has been genuinely dramatic: strong Phase 2 trial results and Breakthrough Therapy status, followed by a 2024 rejection over trial-design and safety concerns, with a resubmitted application reported in August 2026 and still pending. Its real dangers include hyperthermia (and, less intuitively, dangerous overhydration from over-correcting for it), serotonin syndrome in certain combinations, and — the single biggest practical risk today — a street supply frequently adulterated with entirely different, unlabeled substances. Try this: if MDMA use is part of your or someone else's life, prioritize reagent testing the actual substance — adulteration, not MDMA itself, is the leading real-world risk. Sources & Further Reading Sources - MDMA's 1912 synthesis, Shulgin's 1970s rediscovery, and its use in underground therapy before 1985 scheduling reflect documented pharmacological and drug-policy history. - MDMA-assisted therapy's clinical trial history and 2024 FDA rejection reflect published FDA and pharmaceutical-industry reporting; the resubmission: Psychedelic Alpha, "Two Years After Rejection, Resilient Quietly Refiles MDMA for PTSD Application" (August 2026), and MAPS's response (10 August 2026). - Hyponatremia and hyperthermia risk, and current harm-reduction fluid-intake guidance, reflect published harm-reduction and clinical literature. - Adulteration prevalence in the illicit MDMA/"Molly" supply reflects published drug-checking service data (including DanceSafe testing results). - Neurotoxicity research context reflects the broader clinical and neuropharmacological literature on MDMA. Go deeper - 🌐 DanceSafe.org — reagent testing information and current adulterant alerts - 🌐 Search "MDMA PTSD FDA resubmission 2026" for the current regulatory status - 🌐 Related pieces in this library: Ayahuasca, this category, for the shared serotonin syndrome/MAOI interaction risk Cannabis: From "Reefer Madness" to Regulated Dispensaries --------------------------------------------------------- In 1937, the United States effectively banned cannabis nationally under the name "marihuana" — a deliberately foreign-sounding spelling chosen partly to associate the drug with Mexican immigrants, part of a public campaign, led by Federal Bureau of Narcotics head Harry Anslinger, that also produced the propaganda film Reefer Madness. Ninety years later, the same plant is sold in licensed, taxed dispensaries across most of the country. Few drugs in this category have had their legal status reverse this completely, or this recently. Thousands of years before any of that Cannabis has been used by humans for at least 5,000 years, and likely longer — archaeological evidence includes hemp fiber cordage dating back roughly 10,000 years, and burnt cannabis residue with unusually high psychoactive potency found in wooden braziers at a roughly 2,500-year-old cemetery in the Pamir Mountains, suggesting deliberate ceremonial use of a cultivated, more potent strain rather than accidental exposure. The plant spread through India, where it holds a specific religious association with Shiva and remains used in traditional preparations like bhang, and through the Islamic world as hashish, well before it became a subject of American drug policy at all. A ban built substantially on who was using it, not what it did Cannabis use in the early 20th-century United States became associated in the public imagination with Mexican immigrants and, separately, with Black jazz culture — associations that Anslinger's campaign leaned on directly and explicitly to build political support for prohibition, a pattern of racialized drug policy that recurs across this category's history (see also this category's piece on opium). The Marihuana Tax Act of 1937 made cultivation and possession effectively illegal nationwide; the Controlled Substances Act of 1970 later placed it in Schedule I, the most restrictive federal category, alongside heroin and LSD — a classification legally asserting no accepted medical use, despite a documented history of exactly that use dating back millennia. The reversal, state by state California's Proposition 215 in 1996 made it the first U.S. state to legalize medical cannabis; Colorado and Washington became the first to legalize recreational adult use in 2012. As of October 2026, 24 states plus Washington, D.C. have legalized recreational adult use (no state has been added since 2023), and roughly 40 states allow some form of medical cannabis. Federally, a December 2025 executive order led the DEA, in April 2026, to move FDA-approved marijuana products and state-licensed medical marijuana to the less restrictive Schedule III; all other cannabis, including recreational adult-use products, remains Schedule I while a broader rescheduling proceeding continues. The gap between state legality and federal scheduling remains a real, unresolved tension: it affects everything from banking access for dispensaries to whether cannabis businesses can take standard federal tax deductions. What's genuinely changed about the product itself One honest, important fact often missing from the legalization conversation: modern cannabis is, on average, considerably more potent than the cannabis of the 1960s-80s counterculture era — a well-documented trend across cultivation research and industry data, driven by decades of selective breeding for higher THC content, and further amplified by the now-widespread availability of concentrated products (extracts, vapes, "dabs") with far higher THC concentrations than flower alone. This matters directly for the risk section below, since several of cannabis's real risks scale with potency and frequency, not just with use itself. The real dangers No established fatal overdose from THC toxicity alone — this genuinely distinguishes cannabis from most other drugs in this category, and it's real and worth stating plainly. Cannabis Use Disorder is real, not a myth. Somewhere between roughly 9% and 30% of regular users develop a genuine dependence, with risk substantially higher for people who start in adolescence and for daily or near-daily users — "cannabis isn't addictive" is an oversimplification that doesn't hold up against the clinical evidence. Psychosis risk, particularly with high-potency products and adolescent use. This is the single most serious, well-established risk associated with modern cannabis: regular use of high-THC products, especially starting in adolescence and especially in people with a personal or family history of psychosis, is associated with a meaningfully increased risk of developing psychosis or schizophrenia. This isn't a fringe concern — it's one of the most consistently replicated findings in cannabis research, and it's specifically amplified by the rising potency described above. Adolescent brain development. The brain's frontal cortex continues developing into the mid-20s, and regular cannabis use during this window is associated with measurable effects on attention, memory, and learning that are less pronounced in adult-onset users. Edible-specific overconsumption risk. Edibles take considerably longer to produce effects than smoking or vaping (often 30–90 minutes), which leads many users to consume more before feeling anything, then experience an overwhelming, prolonged effect once it finally hits — a genuinely common, avoidable bad experience, and also a real poisoning risk for children who mistake THC edibles for ordinary candy. Cannabinoid Hyperemesis Syndrome. An increasingly recognized condition in chronic, long-term heavy users: cyclic, severe vomiting that — counterintuitively — is often relieved specifically by hot showers, and resolves with sustained abstinence. "Weed is basically harmless" and "weed causes schizophrenia" are both oversimplifications of the same real, more specific finding: risk concentrates heavily in high-potency products, adolescent use, and people with a personal or family history of psychosis — not in occasional adult use of moderate-potency products. The genuine medical case Unlike several other drugs in this category, cannabis has real, reasonably well-established medical value: effective treatment for chronic pain, chemotherapy-induced nausea and vomiting, and muscle spasticity in multiple sclerosis are among its better-evidenced uses. A CBD-based cannabis medication (Epidiolex) is FDA-approved specifically for certain severe, treatment-resistant childhood epilepsy syndromes. Evidence for anxiety and sleep is more mixed — some users report real benefit, while regular use can also worsen anxiety in others, and the direction of effect appears to depend significantly on the individual and the specific product used. Try this If you use cannabis products, check the THC percentage on the label (in legal markets, it's required) and compare it mentally to the roughly 2–4% potency typical of cannabis a few decades ago — the difference is a genuinely useful frame for understanding why "the same drug I used in college" may not be an accurate comparison anymore. The takeaway Cannabis has been used by humans for thousands of years, was banned in the U.S. substantially due to racialized political campaigning in the 1930s, and has reversed course dramatically in recent decades — now recreationally legal in 24 U.S. states while remaining federally Schedule I, with reclassification to Schedule III proposed but not yet completed. Modern cannabis is considerably more potent than historical cannabis, which matters directly for its most serious real risk: psychosis, particularly with high-potency products, adolescent use, and a personal or family history of psychosis. It also has genuine, well-evidenced medical value for chronic pain, chemotherapy-related nausea, and specific severe epilepsy syndromes. Try this: check the THC percentage on any cannabis product you use and compare it to historical potency levels — it changes how "the same drug people always used" should actually be understood today. Sources & Further Reading Sources - Ancient and ceremonial cannabis use, including the Pamir Mountains brazier findings, reflects published archaeological research. - The 1937 Marihuana Tax Act, Harry Anslinger's campaign, and their documented racialized framing reflect published U.S. drug-policy history. - Current state legalization status reflects Marijuana Policy Project and Pew Research Center tallies. Federal status: Executive Order of 18 December 2025; DEA final order, Federal Register, 28 April 2026 (2026-08176), rescheduling FDA-approved and state-licensed medical marijuana to Schedule III; Morgan Lewis, "Post–DEA Hearing, Broader Marijuana Rescheduling Questions Remain" (September 2026). - Cannabis Use Disorder prevalence, psychosis risk research, and adolescent brain development findings reflect published clinical and epidemiological research. - Medical cannabis evidence (chronic pain, chemotherapy-induced nausea, Epidiolex for epilepsy) reflects standard clinical and FDA documentation. Go deeper - 🌐 Search "cannabis potency THC increase decades research" for the trend data behind this piece's potency discussion - 🌐 Search "cannabis psychosis risk adolescent research" for the clinical literature behind this piece's most serious risk finding - 🌐 Related piece in this library: Opium, this category, for a parallel case of racialized U.S. drug-policy history Nicotine & Tobacco: The Deadliest Drug in This Entire Category -------------------------------------------------------------- Every other substance in this category carries real, documented risk. Only one of them is a leading cause of preventable death worldwide, used daily by hundreds of millions of people, entirely legally, sold at nearly every convenience store on Earth. That drug is nicotine, delivered overwhelmingly through smoked tobacco — and its story includes one of the most thoroughly documented cases of corporate deception in modern industrial history. Sacred plant, then mass commodity Tobacco was used ceremonially and medicinally by Indigenous peoples across the Americas for thousands of years before European contact — pipe ceremonies held genuine spiritual and social significance in many Native American cultures, a use fundamentally different in both scale and meaning from what followed. European colonizers brought tobacco back across the Atlantic in the 16th century, where it was initially marketed as a medicinal cure-all before becoming an enormous commercial commodity. The invention of the cigarette-rolling machine in the 1880s (the Bonsack machine) turned tobacco from a hand-rolled or pipe-smoked product into a mass-manufactured one, and both World Wars further normalized cigarette smoking by including cigarettes directly in military rations — smoking peaked in the mid-20th century United States at roughly 40–45% of all adults. The deception, documented in the companies' own words What makes tobacco's modern history particularly notable isn't just its harm — it's that the industry itself was proven, through its own internal documents made public in litigation, to have known about smoking's cancer and addiction risks for decades while publicly funding doubt and denial. This wasn't ambiguous inference; internal tobacco company research from as early as the 1950s and '60s documented real knowledge of both nicotine's addictiveness and tobacco's carcinogenic effects, information the industry actively worked to obscure from the public and regulators for decades afterward. The U.S. Surgeon General's landmark 1964 report on smoking and health became the turning point that began reversing public opinion and use, though it took decades more litigation before the industry's internal knowledge became fully public — culminating in the 1998 Master Settlement Agreement, in which major tobacco companies agreed to pay U.S. states over $200 billion and accept significant marketing restrictions. The real dangers It remains a leading cause of preventable death worldwide, through a wide range of mechanisms — lung cancer and numerous other cancers, heart disease, stroke, and chronic obstructive pulmonary disease (COPD) chief among them. Unlike most other drugs in this category, the primary harm doesn't come from nicotine's psychoactive effects — it comes from the thousands of other chemical compounds produced by burning tobacco and inhaling the resulting smoke directly into the lungs, repeatedly, over years. Nicotine itself is one of the most addictive substances known, with dependence often developing quickly and proving genuinely difficult to overcome — a huge share of smokers report wanting to quit and having tried multiple times, a pattern consistent with nicotine's specific and well-studied addictive mechanism. Secondhand smoke carries real, documented risk to non-users — a genuine harm-to-others dimension, similar in kind (though generally smaller in absolute scale) to alcohol's harm-to-others profile covered elsewhere in this category. The shift to vaping, and what's actually known so far Cigarette smoking has fallen to a historic low in the U.S. — 9.9% of adults in 2024, the first time below 10% (CDC National Health Interview Survey, reported in 2026) — but vaping and e-cigarette use has risen in its place, to about 7% of adults, and among 18- to 24-year-olds vaping (14.8%) now far outstrips cigarette smoking (3.4%). Vaping avoids combustion and the specific chemical byproducts of burning tobacco, which appears to make it meaningfully less harmful than combustible cigarettes for the specific outcomes studied so far — but "less harmful than cigarettes" is a very different claim from "safe," and long-term data on vaping's health effects is still considerably less mature than the many decades of cigarette research behind those numbers. A real, documented acute risk did emerge in 2019: EVALI (e-cigarette or vaping-associated lung injury), an outbreak of serious lung injuries traced substantially to vitamin E acetate, an additive found specifically in certain illicit THC vape cartridges — a useful reminder that vaping-related risk depends significantly on exactly what's being vaped and from what source, not just the act of vaping itself. Nicotine kills more people than nearly every other drug in this category combined, and it does it legally, quietly, and mostly through a delivery mechanism — burning and inhaling — that has almost nothing to do with nicotine's own psychoactive effects. The newest front: youth and nicotine pouches Flavored, high-nicotine vape products have become a specific and ongoing public health concern for adolescents in recent years, though youth e-cigarette use has actually declined somewhat according to the most recent national youth surveys. A newer product category — oral nicotine pouches (brands like Zyn) — has also grown quickly, marketed as a smoke-free, spit-free alternative; their long-term health profile is even less studied than vaping's, simply because they're newer to the market. Is there any benefit case? Essentially none, from the standpoint of smoked or vaped tobacco products — this is the category's clearest case of a substance with overwhelming, well-documented harm and no meaningful offsetting benefit for the vast majority of users. Nicotine itself, isolated from delivery method, has a narrow research history as a potential cognitive aid in specific neurological contexts (some research into attention and certain neurodegenerative conditions), but this remains a niche, early-stage research area, nowhere close to justifying real-world tobacco or vape use, and entirely separate from how the vast majority of nicotine is actually consumed. Try this If you smoke or vape and are considering quitting, know that nicotine replacement therapy (patches, gum, lozenges) combined with behavioral support roughly doubles quit success rates compared to trying alone — a genuinely evidence-backed, accessible first step. The takeaway Tobacco has deep ceremonial roots in Indigenous American cultures, but its modern global harm stems from mass commercial cigarette production and a documented, decades-long corporate campaign to obscure known cancer and addiction risks — one of the best-documented cases of institutional deception in modern industrial history. It remains a leading cause of preventable death worldwide, driven mostly by the chemistry of combustion rather than nicotine's psychoactive effects alone. Cigarette smoking has fallen to a historic low as vaping has risen in its place — likely somewhat less harmful than cigarettes for the specific outcomes studied, but still new enough that long-term risk remains genuinely less understood than cigarettes' well-established harm. Try this: if quitting is on your mind, look into nicotine replacement therapy combined with behavioral support — it roughly doubles quit success rates compared to trying alone. Sources & Further Reading Sources - Indigenous ceremonial tobacco use and the history of commercial cigarette manufacturing reflect standard historical documentation. - Tobacco industry internal knowledge of cancer and addiction risk, and the 1998 Master Settlement Agreement, reflect documented litigation history and publicly released internal industry documents. - The 1964 Surgeon General's report reflects official U.S. government documentation. - Current smoking and vaping statistics: CDC National Center for Health Statistics, 2024 National Health Interview Survey data (Health E-Stat 115, March 2026; summarised by CIDRAP, March 2026). - EVALI's association with vitamin E acetate in illicit THC vape products reflects CDC outbreak investigation findings. Go deeper - 🌐 CDC.gov/tobacco — current smoking and vaping statistics and quitting resources - 🌐 Search "tobacco industry internal documents cancer knowledge history" for the documented corporate deception history - 🌐 Related piece in this library: Alcohol, this category, for another legal drug with a significant harm-to-others dimension Ketamine: A Battlefield Anesthetic That Became a Psychiatric Breakthrough ------------------------------------------------------------------------- In 2000, a small study found that a single low-dose IV infusion of a decades-old battlefield anesthetic produced rapid, significant relief from depression — in some patients, within hours, for a condition where standard antidepressants typically take weeks to work at all, if they work. That finding launched what's now one of the more genuine, FDA-recognized psychiatric breakthroughs of the last quarter-century, running in parallel with the drug's much older reputation as a club-scene dissociative. From battlefield to nightclub to psychiatrist's office Ketamine was synthesized in 1962 by chemist Calvin Stevens as a safer replacement for PCP, and the FDA approved it as an anesthetic in 1970. Its specific medical value was quickly proven under the worst possible test conditions: it became a widely used field anesthetic during the Vietnam War, valued specifically because, unlike many other anesthetics, it doesn't significantly suppress breathing or blood pressure — a genuinely important safety property in a battlefield setting without full monitoring equipment. It remains in common medical and veterinary use as an anesthetic today. Recreational use under the name "Special K" emerged in club and party scenes starting in the 1980s, centered on ketamine's distinctive dissociative effects — at higher doses, a state often called the "k-hole," an intense, often disorienting separation from ordinary body and reality perception. The depression breakthrough The landmark 2000 study in Biological Psychiatry (Berman and colleagues at Yale) was a tiny placebo-controlled trial — seven patients completed it — in people with major depression, and it showed relief within hours. In 2006 a larger trial at the U.S. National Institute of Mental Health (Zarate and colleagues, 18 patients, in Archives of General Psychiatry) confirmed the rapid effect specifically in treatment-resistant depression — people for whom standard antidepressants (which work on a fundamentally different, slower-acting mechanism) had already failed. This was a genuinely novel finding: nothing in psychiatry's existing toolkit worked this fast. In 2019, the FDA approved esketamine (brand name Spravato), a nasal spray formulation derived from ketamine, specifically for treatment-resistant depression — the first ketamine-derived medication to receive that approval. Since then, ketamine clinics — offering off-label IV or intramuscular ketamine treatment for depression, generally outside the specific Spravato protocol — have grown from a handful to an estimated hundreds or thousands of locations across the U.S. What it actually does, and the real dangers Ketamine is a dissociative anesthetic — at sub-anesthetic (lower) doses, it produces a sense of detachment from the body and surroundings alongside its antidepressant and mild analgesic effects; at higher doses, it produces genuine anesthesia (loss of consciousness and pain sensation) and, at unsupervised recreational doses, the k-hole. Impaired coordination and judgment during dissociation is a real, immediate safety risk. Someone dissociated from their body and surroundings is at real risk of injury — falls, accidents, an inability to respond to danger — which is exactly why clinical ketamine treatment happens in a monitored medical setting, and why unsupervised recreational use in an uncontrolled environment carries meaningfully more risk than the clinical version of the same drug. Chronic heavy recreational use causes real, sometimes permanent bladder damage. This is a well-documented, serious condition called ketamine-induced cystitis (sometimes described as "ketamine bladder") — chronic heavy use can cause ulceration and inflammation of the bladder lining, leading to pain, urinary urgency, incontinence, and in severe, longstanding cases, permanent bladder shrinkage and damage requiring surgical intervention. This is a genuinely underrecognized risk specific to ketamine among the drugs in this category. "K-pains." Chronic heavy users also report severe abdominal pain, sometimes called K-pains or K-cramps, another distinctive marker of heavy long-term use. Dangerous combined with other depressants. Combining ketamine with alcohol or other sedating drugs compounds respiratory and cardiac risk, similar to the combination dangers described for benzodiazepines elsewhere in this category. Not classically physically addictive like opioids, but real psychological dependence patterns exist, particularly with frequent recreational use, and tolerance can build with regular use. Ketamine is a rare case in this category where the same molecule, at a lower dose in a monitored clinical setting, represents one of psychiatry's most promising recent tools — and, at higher doses in an unsupervised recreational setting, carries real risks including a specific, serious, and often overlooked risk to bladder health that has nothing to do with its psychiatric promise at all. The genuine promise, stated honestly Ketamine and esketamine represent a real, FDA-recognized advance specifically for treatment-resistant depression — a population that, by definition, hasn't responded to other available treatments, and for whom a rapid-acting option is a meaningful clinical addition, not a marginal one. Active research is exploring ketamine's potential for PTSD, OCD, and certain substance use disorders as well, though these applications remain earlier-stage and less established than the depression evidence. Try this If ketamine touches your life — clinically or recreationally — know the specific bladder-damage risk described above; it's one of the least publicly known serious risks in this entire category, disproportionate to how much attention it typically gets compared to more famous psychedelic risks. The takeaway Ketamine has lived two very different lives since 1962: a genuinely valuable battlefield and medical anesthetic, and — since a landmark 2000 study — one of psychiatry's most promising recent tools for treatment-resistant depression, formalized in the FDA-approved esketamine nasal spray in 2019. It also has a long-running recreational history as a club dissociative, "Special K," where unsupervised use at higher doses carries real risk of injury during dissociation and, with chronic heavy use, a serious and often underrecognized risk of permanent bladder damage. The clinical and recreational versions of this drug carry meaningfully different risk profiles, driven substantially by dose, setting, and supervision. Try this: if ketamine is part of your life in any form, learn the specific signs of ketamine-induced bladder damage — it's one of the most serious, least publicized risks in this entire category. Sources & Further Reading Sources - Ketamine's 1962 synthesis, 1970 FDA anesthetic approval, and Vietnam War battlefield use reflect standard pharmacological and medical history. - Berman RM, et al., "Antidepressant effects of ketamine in depressed patients," Biological Psychiatry 47 (2000): 351–354; Zarate CA Jr, et al., "A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression," Archives of General Psychiatry 63 (2006): 856–864. The 2019 FDA esketamine (Spravato) approval reflects published regulatory documentation. - Ketamine-induced cystitis and "K-pains" reflect published clinical and urological case literature. - Current ketamine clinic prevalence reflects current 2026 industry and clinical reporting. Go deeper - 🌐 Search "ketamine cystitis bladder damage symptoms" for detailed clinical information on this underrecognized risk - 🌐 NAMI.org — information on ketamine and esketamine as depression treatments - 🌐 Related pieces in this library: The Real Harm Ladder, this category, and Psilocybin, for another substance with a parallel rapid clinical-legitimacy trajectory